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Ac   acetyl 
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The growing understanding of RNA´s functional repertoire has opened a new view 
to not just life itself, but also for our ability to control gene expression and thus 
regulate cell processes. Since the discovery of first catalytic RNAs in early 
1980s,1,2 the initial concept of passive RNA responsible only for the transfer of 
information between DNA and protein synthesis, has greatly changed. Besides the 
“classic” categories of RNA in the translation process, i.e. messenger RNA 
(mRNA), transfer RNA (tRNA) and ribosomal RNA (rRNA), we now know that 
various non-protein-coding RNAs participate in cellular regulation at different 
levels.3 The diverse RNA family in eukaryotes includes small regulatory RNAs 
(Section 1.1.1.1), ribozymes (RNAs with enzymatic activity) and even riboswitches 
(RNA sensors in mRNA that are capable of modulating gene expression in 
response to internal and external inputs) although the last mentioned are mostly 
found in prokaryotes.4 They all interact through a combination of complementary 
base pairing, protein complexing, and catalysis. It has been estimated that less than 
2% of the human genome is translated into protein, yet more than 40% of the 
genome is thought to be transcribed into RNA.5 
 
As RNA’s real capacity has started to reveal, drug design based on RNA-targeting 
has become an attractive alternative to traditional drug discovery focused on 
protein-targets. Selective gene-silencing offers high therapeutic potential, since in 
principle any single gene within the genome can be silenced by affecting its mRNA 
transcript.6-9 The recognition takes place via Watson-Crick base pairing (Figure 1) 
and is, hence, sequence-specific. The technology shows considerable opportunities 
in combating against major human health threats, such as cancer10-12 and viral 
infections13. For this purpose, the natural cellular mechanism called RNA 
interference (RNAi) has recently received a vast interest.14-19 RNAi can be 
triggered by synthetic double-stranded RNAs, as was described for the first time in 
1998 with a nematode caenorhabditis elegans.20 For this achievement, Fire and 
Mello received a Nobel Prize in 2006. The pioneering work employing synthetic 
oligonucleotides as therapeutic agents had, however, started already in 1978, when 
Zamecnik and Stephenson made experiments with single-stranded antisense 
oligodeoxynucleotides and managed to prevent translation of Rous Sarcoma virus 
(RSV) RNA in vitro.21,22 This led to early development of an antisense 
oligonucleotide approach: a novel concept of blocking sequence-specifically 
disease related genes by introduction of a synthetic complementary strand (the 
antisense strand) to the cell (Figure 2). Besides nucleic acids, cellular RNA may be 


















































































RNA: R = H (Ura), X = OH
DNA: R = Me (Thy), X = H
 
 






Figure 2. Antisense principle and the action of conventional protein targeting drug.  
 
Currently, only one antisense drug (1998, Vitravene®) and one aptamer 
oligonucleotide (2004, Macugen®, aptamer = molecule that bind to a specific 
target molecule such as protein acting frequently like an antibody) have been 
approved by the FDA.19 They both are for the treatment of an eye disease as is the 
first RNAi based human-therapeutics, which entered clinical trials at 2004. High 





number of challenges that the technology needs to overcome. These problems are 
approached through chemical modifications of the antisense oligonucleotides and 
exploitation of conjugations to other molecules.26-32 The modifications are aimed at 
enhancing hybridization specificity and affinity to the target RNA, to increase 
stability towards nuclease degradation, to decrease toxicity and finally to improve 
pharmacokinetics and cellular uptake of the drug. 
 
1.1 Antisense strategies 
Strategies that target mRNA and, hence, prevent its translation into protein include 
the use of single stranded antisense oligonucleotides (Section 1.1.2), nucleic acid 
enzymes (ribozyme and DNAzyme) and double-stranded small interfering RNA 
(siRNA or miRNA, Section 1.1.1).8 In general, post-transcriptional gene silencing 
(PTGS) means down-regulation of a gene at the RNA level, i.e. after transcription 
without a need to manipulate the host genome. Antisense mechanisms based on 
PTGS can be divided into two main categories: those that interfere with RNA´s 
function without promoting RNA degradation and those that induce 
degradation.17,31  
 
1.1.1 RNA interference 
1.1.1.1 Small regulatory RNAs  
Small RNAs are around 20-30 nucleotide long RNA molecules that are found in 
almost all eukaryotic organisms.3,18 Their function is to control endogenous genes 
and defend the cell against invasive nucleic acids such as viruses, transposons and 
transgenes. This control is generally inhibitory and often takes place by interfering 
with mRNA translation. Three main groups of small RNAs are identified: short 
interfering RNA (siRNA), micro RNA (miRNA) and piwi-interacting RNA 
(piRNA). From these, siRNA and miRNA are best known and their presence in 
cells triggers a cellular mechanism called RNA interference (RNAi). RNAi 
depends on many protein interactions and refers to a natural gene regulatory 
system, wherein double-stranded RNAs (dsRNA) inhibit the expression of 
complementary genes.  
 
1.1.1.2 The mechanisms of RNAi  
In mammalian cells, the RNA interference is primarily a process of PTGS and the 
gene expression is suppressed in the cytoplasm by degrading mRNA or directly 
repressing translation.19 The importance of RNAi for mammalian transcriptional 
gene silencing (TGS) at the DNA level by inhibition of transcription in the nucleus 
has not yet been clearly demonstrated. Figure 3 illustrates the siRNA and miRNA 







Figure 3. Simplified model for the RNAi mechanism by siRNA and miRNA.3,14 
 
siRNAs are approximately 21-23 nucleotide long duplexes having 2-base 3´-
overhangs and 5´-phosphate groups.3,18,19 They are processed by endoribonuclease 
enzyme called Dicer from larger dsRNA duplexes, which derive either from 
endogenous sources or are taken up from the environment. Hence, the siRNAs 
participate in cell´s defend mechanisms and regulate protein-coding genes. The 
actual effector of the RNAi is a ribonucleoprotein complex RISC (RNA-induced 
silencing complex), which is guided by the siRNA to the complementary target 
RNA. In RISC, the strand with a lower binding affinity at its 5´-end becomes the 
antisense (guide) strand of the siRNA and the sense (passanger) strand is degraded. 
The remaining single-stranded antisense strand then directs the sequence-
specificity of silencing by RISC. The target mRNA is cleaved at a specific site in 
the center of the duplex, i.e 10 nucleotides from the 5´-end of the siRNA strand. 
The catalytic component of RISC that degrades the target RNA is a protein 
Argonaut 2 (Ago2) containing an RNase H like domain (see Section 1.1.2). 
 
miRNAs are evolutionarily conserved from plants to animals and encoded by 
specific genes to regulate many biological processes including development, 





about 30% of all protein-coding genes in mammals.19 That is why they have 
emerged as biomarkers of distinct biological states and play an important role in 
many diseases, such as viral infections and cancer, in which miRNAs are shown to 
act as either oncogenes (gene that has the potential to cause cancer) or tumor 
suppressors.3,12,19 Whereas siRNA pathway requires perfect sequence 
complementarity to the target RNA, miRNA can bind with mismatches. miRNA 
precursors contain hairpin structures, often with bulged regions, which are 
processed by the enzymes Drosha (in the nucleus) and Dicer (in the cytoplasm) into 
approximately 22 nucleotide long duplexes resembling siRNAs. One strand of the 
duplex incorporates into a RISC-like miRNA-ribonucleoprotein (miRNP) complex 
including Ago protein. As with siRNA, the relative thermodynamic stability of the 
miRNA strands usually determines the guide strand.18 Preferential recognition of 
the target sequences by miRNA occurs in the 3´-untranslated region (3´-UTR) of 
the mRNAs. The degree of miRNA-mRNA complementarity seems to be an 
important factor as to, whether miRNAs induce mRNA degradation or repress their 
translation. The precise mechanism is still unclear. Unlike in siRNA pathway, 
miRNA induced mRNA degradation seems to be initiated by deadenylation, 
decapping or exonucleolytic digestion.  
 
The biogenesis and mechanisms of siRNA and miRNA pathways clearly 
overlap.12,18 One important difference between them concerns their self-silencing 
ability. As defense molecules, siRNAs typically silence the same DNA or RNA 
sequence from which they were derived, making their production a continual 
struggle against themselves. siRNAs are highly specific to individual gene targets, 
whereas miRNAs can bind to multiple transcripts and each gene target can have 
multiple miRNA-binding sites. Hence, most miRNAs silence other than their own 
genes and the demand to bind heterologous targets makes them more constrained 
and less adaptable for defense purposes.   
 
1.1.2 Antisense oligonucleotides 
Before the discovery of natural regulatory RNAs and their function in cell biology, 
the antisense strategy, exploiting synthetically prepared single-stranded antisense 
oligonucleotides (ASO), had already evolved.7-10,33 ASO molecules are typically 
12-25 nucleotides long nucleic acid analogs designed to inhibit the function of an 
RNA target. After passing through the cell membrane and entering the cytoplasm 
and/or nucleus, an antisense oligonucleotide hybridizes with its target mRNA and 
interacts by a mechanism depending on its chemical composition and location of 
the hybridization (Figure 4). Two main cellular mechanisms that contribute to their 
activity are activation of RNase H leading to mRNA degradation and translational 
arrest blocking the binding to ribosome. Additional mechanisms include 
interference with mRNA maturation by inhibition of splicing and destabilization of 







Figure 4. Modes of PTGS action of antisense oligonucleotides.9 
 
The most extensively used and best understood ASO mechanism is based on 
induction of RNase H enzyme.7,33,34 As a ubiquitous endonuclease (enzyme that 
cleaves the phosphodiester bond within a polynucleotide chain), it cleaves the RNA 
strand of an RNA-DNA heteroduplex, usually close to the center of the targeted 
RNA. The precise recognition elements for RNase H are unknown, but 
oligonucleotides having DNA-like properties, such as short as tetramers, can result 
in activation. The normal function of RNase H is to help the removal of RNA 
primers in DNA replication, but it may play other roles in the cell and although its 
concentration is thought to be greater in the nucleus, it is also found in the 
cytoplasm.33 In addition to RNase H, there are other RNases present in cells that 
may be exploited in a similar manner.10  
 
1.1.3 Comparing antisense approaches 
Obviously, the antisense oligonucleotide and siRNA approaches have a lot in 
common and the methodological development benefits from each other. There is no 
clear evidence that one antisense mechanism would be superior to another and the 
true potency of both approaches will be assessed only by real clinical 
development.32,35 The following demonstrates a few most notable differences. 





oligomers must find their targets unassisted, since there seems to be no evolved 
cellular mechanism for promoting antisense strand recognition in contrary to RISC 
incorporating siRNA. On the other hand, siRNAs cannot target nuclear RNAs or 
introns in contrast to ASOs and, hence, RNAi is restricted to cytoplasm. Some 
concern has been raised for possible disturbance and toxicity that synthetic siRNAs 
may have for the native cellular RNAi machinery responsible for many important 
physiological processes (off-target effect).  
 
1.2 Cell delivery of oligonucleotides  
The delivery of oligonucleotides to cells is one of the major challenges for 
antisense technologies, as far as the systemic (i.e. affecting the entire body) 
delivery in vivo is concerned. Oligonucleotide drugs enter the cell most probably 
via some form of endocytosis, which involves the association of the drug molecule 
either to the cell membrane (adsorptive endocytosis) or to a membrane-bound 
receptor (receptor-mediated endocytosis) and results in vesicular uptake.26,29,36,37 
The large size, hydrophilic character and anionic backbone of nucleic acids prevent 
a direct cellular permeation process at any significant level. After internalization to 
the cytoplasm, oligonucleotide vesicles enter the endosome-lysosome 
compartment. Endosomes are membranous organelles that function as intracellular 
sorting centers. If the oligonucleotide is unable to escape the endosome, as often is 
the case, it is likely to be degraded by lysosome and fails to reach its site of action 
in the cytosol or nucleus. Efficient endocytosis requires cooperative action of all 
the stages of cell delivery: cellular uptake, vesicular trafficking and finally 






















When unmodified naked oligonucleotides are added to cells, an inefficient cellular 
uptake is observed.36 The adsorption to the cell surface is complicated by the 
negative charges in both oligonucleotide and membrane, causing ionic repulsion. 
However, simple elimination of the negative charge alone does not improve 
cellular uptake, as demonstrated by neutral oligonucleotide mimics incorporating 
methylphosphonate  and PNA analogues (see structures in Section 1.3.2.1).26 In 
addition, both unmodified and uncharged oligonucleotides tend to have low binding 
to proteins within blood plasma and are therefore rapidly excreted in the urine 
reducing delivery to tissues.31 Consequently, numerous chemical modifications and 
conjugate groups have been studied for their ability to facilitate cellular uptake and 
bioavailability in vivo (Section 1.3).  
 
Besides being able to improve cellular uptake of the oligonucleotide, the conjugates 
that allow targeted delivery are highly desirable. Cell-type-specificity would not 
only minimize the chance of potential adverse effects, but would also reduce the 
required dose to achieve therapeutic effect.30 Receptors are proteins that are 
embedded in the plasma membrane and form a binding site for a specific molecule. 
Oligonucleotide that is conjugated with a targeting moiety can be recognized by 
cell-surface receptor and mediate the internalization of nucleic acid through 
receptor-mediated endocytosis. The employed cell-specific ligands include 
aptamers, antibodies, sugar molecules (Section 1.3.3.5), vitamins (Section 1.3.3.1) 
and hormones. 
 
On the other hand, one way to resolve all the problems related to the endocytosis-
mediated uptake would be to bypass it.26,37 Direct penetration through cell 
membrane would be an energy-independent route but also unspecific for cell- and 
tissue-type, which can be good or bad. This type of non-endocytic delivery has 
been pursued with positively charged cell penetrating peptides (Section 1.3.3.2) 
such as TAT or Penetratin. Although it appears that endocytosis persists to be the 
main uptake pathway for these peptides, the possibility of direct penetration cannot 
be excluded. Other non-endocytic delivery techniques include microinjection, 
permeabilization and electroporation that are not, however, compatible with gene 
delivery in vivo due to their highly invasive nature.37 In microinjection each cell is 
injected with the gene using glass capillary pipettes. Permeabilization uses pore-
forming agents that are able to induce transmembrane channels or large apertures in 
the cell membrane, which then allow the entry. Finally, the electroporation 
technique involves the use of an electric field that opens pores in the cell.  
 
In general, the mechanisms related to cell delivery of oligonucleotides are complex 
and still not well understood. Compared to cellular uptake, the nuclear entry may 
not be the rate-limiting step for free oligonucleotides since they are shown to 
continuously shuttle between the nucleus and cytoplasm.29  
 
1.3 Chemical modifications of nucleic acid drugs 
Regardless of the immense attractiveness of gene silencing as a therapeutic 





first biological barriers encountered by siRNAs or antisense oligonucleotides is the 
nuclease activity in plasma and tissues as natural phosphodiester bonds are rapidly 
degraded in vivo. Even though the double stranded siRNAs are more stable against 
nuclease attack than their single-stranded counterparts, the protection is needed. 
The relatively large polyanionic nucleic acids do not easily cross cell membranes 
and, hence, exhibit inefficient cellular uptake and poor bioavailability. Their cell 
targeting is unspecific and the distribution in tissues and intracellular media is 
limited. Moreover, oligonucleotides may have toxic side effects, which are 
classified as hybridization dependent or hybridization independent.8,31 The former 
class can be attributed to exaggerated pharmacological effects and hybridization to 
non-target RNA instead of the intended mRNA. This hybridization dependent off-
targeting can be minimized by careful selection of the target. siRNAs can 
additionally have unwanted participation in miRNA pathways. Hybridization 
independent toxicity is related to the chemically modified oligonucleotides but may 
still exhibit some sequence specificity arising from motifs that define a receptor 
interaction and trigger an immune response.  
 
A wide variety of chemical modifications and conjugate groups have been 
introduced into oligonucleotides to overcome the problems discussed above. 
Section 1.3.2 will summarize some of the most well-known structural 
modifications used in oligonucleotides and in Section 1.3.3 those covalently 
attached conjugate groups that are aimed at facilitating the delivery are discussed. 
In general, conjugation refers to covalent attachment of functional molecules to 
nucleic acids. All three structural subunits in nucleic acids, i.e. ribose sugar, 
phosphate backbone and base moiety have been modified and functionalized. No 
single modification covers all the desired properties and, hence, their combinations 
are common. The ideal oligonucleotide structure appears to be case and application 
dependent. 
 
1.3.1 General remarks for oligonucleotide design 
If the antisense oligonucleotide is intended to utilize the RNase H dependent 
pathway, the chemical modifications have to support it. The nucleoside 
conformation is a critical factor for the activity of RNase H, which is destined to 
degrade the RNA strand in a DNA/RNA hybrid and fails to use RNA/RNA duplex 
as a substrate.34 While higher thermal stabilities are achieved using modifications 
such as the 2´-modified sugars (analogs of RNA) that adopt an RNA-like 3´-endo 
sugar puckering, they shift the A-B-type helical arrangement of the DNA/RNA 
heteroduplex to the A-type RNA helix and fail to promote RNase H activity. The 
same is true for many other potential nucleotide analogs. This has led to the 
development of a chimeric gapmer strategy, in which a central DNA region capable 
of activating RNase H (often 6-10 nucleotide long) is flanked on the 5´- and 3´-
ends by modified sections.38,39 The modified wings provide antisense efficiency 
based on e.g. increased affinity and nuclease stability. Much more versatile 
arrangements are allowed for oligonucleotides using non-RNase H pathways, 






When modifications are introduced into siRNA-oligonucleotides, it is worth 
bearing in mind that care should be exercised while increasing stability towards 
target mRNA.19,28 Since the siRNA strand having weaker base paring at its 5´-end 
is favored as an antisense strand in RISC, the over stabilization may lead to wrong 
strand selection causing off-targeting and problems in unwinding of siRNA duplex. 
By contrast, a high-affinity modification, such as LNA, at the 5´-end of the sense 
strand is often beneficial as also is high-binding affinity at 3´-end of the antisense 
strand. Besides wrong strand selection, off-targeting can arise from unwanted 
participation of siRNAs to miRNA-pathways. This can be reduced with 
modifications at seed region or at 5´-end of the antisense strand. siRNA design 
demands careful strategic modulation of both strands for maximal efficiency. In 
general, bulkier modifications and conjugate groups are better tolerated at the 
terminal positions of the oligonucleotides. The most conventional synthetic siRNA 
structure mimicking the natural product of the Dicer enzyme is shown in Figure 6. 
The 3´-overhangs can be modified in various ways and especially the termini of the 
sense strand accommodates conjugate groups. Chemical phosphorylation of the 




Figure 6. Structure of a siRNA.19  
 
Other kinds of duplex architectures and even single-stranded antisense alternatives 
are also possible for functional siRNAs.28 For example a siRNA made of three 
strands, so-called small internally segmented interfering RNA (sisiRNA), has been 
shown to reduce off-target effects along with increased potency.40 In sisiRNA, the 
antisense strand is kept intact and it is hybridized with two 9-13 nucleotides long 
sense strands. While most of the synthetic duplexes contain 19-21 base pairs, other 
lengths are also possible as long as dsRNAs do not exceed the length of 30 
nucleotides which can trigger the interferon response.28 
 
Besides detailed design of ASOs and siRNAs, search of an accessible target 
sequence within the target RNA plays an important role in efficient gene silencing. 









1.3.2 Structural analogs 
1.3.2.1 Modifications of phosphate linkage and sugar moiety 
The phosphodiester internucleosidic linkage has been modified to increase nuclease 
stability of both antisense oligonucleotides and siRNA (Figure 7).8,9,19,31 
Replacement of the non-bridging oxygen with sulfur (phosphorothioate) is the most 
widely applied and easily synthesized derivative, which is importantly tolerated by 
RNase H and the RNAi machinery. Additionally, phosphorothioate modifications 
in ASO are beneficial for pharmacokinetics as they promote cell delivery by 
binding to proteins in plasma which prolongs their circulation time. The only ASO 
drug approved for clinical use is a 21 base pair long phosphorothioate modified 
oligodeoxynucleotide called Vitravene, which is an anti-viral drug for an eye 
disease caused by a cytomegalo virus. However, if the phosphorothioate content in 
oligonucleotide is high, toxic side effects can result from their tendency to interact 


































Figure 7. Modifications to the phosphodiester backbone enhancing nuclease stability. 
 
Nuclease resistance is also enhanced using e.g boranophosphates, 
phosphoramidates and non-ionic methylphosphonate analogues.27,31 The laborious 
chemical synthesis limits the use of boron derivatives, although they seem to be 
compatible with siRNA function and their activity and nuclease resistance was 
reported to exceed those of the corresponding siRNA having phosphorothioate 
modifications.41 N3´-P5´-Phosphoramidates and methylphosphonates are RNase H 
inactive. Since oligonucleotides, incorporating phosphoramidate linkages, exhibit 
high-affinity binding properties, they are potential antisense agents for steric 
blocking mechanism and their efficiency has been demonstrated in vivo.42  
 
As analogues of oligoribonucleotides, the 2´-position in ribose sugar is 
synthetically easily accessed. 2´-Modifications, such as 2´-O-methyl, 2´-O-
methoxyethyl (MOE), 2´-O-[2-(methylamino)-2-oxoethyl] (NMA) and 2´-fluoro 
groups, increase the binding affinity and nuclease stability (Figure 8).31,39,43 
Furthermore, 2´-derivatives show improved metabolic stability and increased 
lipophilicity. However, these 2´-modifications cannot induce RNase H cleavage of 
the target RNA. To circumvent this, the modifications have been incorporated, as 





RNase H –resistant nucleotides linked to an unmodified region capable of 
activating RNase H. Alternatively, the modified oligonucleotides are employed as 
steric blockers. 2´-O-MOE modified ASOs have demonstrated effective inhibition 
of many viral and cellular gene products both in vitro and in vivo, and MOE 
modifications seem to reduce non-specific protein binding, which can diminish 
toxicity.10,39,44 Similar effects were obtained with 2´-O-NMA derivatives.43 In the 
case of siRNA, 2´-position modifications are generally well-tolerated and the 2´-
OH is not required for recognition by the RNAi machinery.45 Whereas heavily 2´-
O-Me modified oligonucleotides usually decrease RNAi activity, the small 2´-
fluoro substituent is rather compatible with siRNA function and partial 
modifications are tolerated throughout the sense and antisense strands.27,28,32 Both, 
2´-O-Me and 2´-fluoro derivatives have been shown to reduce the 
immunostimulatory effects of siRNA.46,47 Likewise the 2´-fluoro- -D-
arabinonucleotide (FANA) has been shown to be well-tolerated in antisense 
oligonucleotides and siRNA duplexes, in which especially the sense strand can be 
modified.28 Importantly, also DNA nucleosides (2´-H) can be accepted to certain 




Figure 8. 2´-Modified sugar moiety and 4´-thionucleotide.   
 
4´-Thiolation of RNA and DNA, i.e. replacement of the 4´-ring oxygen by sulfur, 
improves thermal stability and nuclease resistance.28,48 Furthermore, 4´-thio-
modifed siRNAs exhibit potent RNAi activity in particularly when antisense and 
sense strands are modified at the end of the chains. 
 
Promising conformationally restricted nucleoside analogs that enhance nuclease 
stability include locked nucleic acid (LNA) and less-strained 2´-O,4´-C-ethylene-
bridged nucleic acid (ENA) (Figure 9).8,49,50 They contain a methylene or ethylene 
bridge that connects the 2´-oxygen of the ribose with the 4´-carbon. Their 
incorporation into oligonucleotides significantly enhances the hybridization 
affinities ( Tm = +3 to +8 °C per monomer) and even though a central positioning 





gapmer has shown to accelerate RNase H cleavage. Chimeric 2´-O-methyl-LNA 
modified oligonucleotides have been targeted to inhibit HIV-1 gene expression 
through steric blocking.51 Although LNA exhibits high potency for ASO, it has 
been reported to increase the risk of hepatoxicity.52 In a recent study, this side 
effect was not detected when the ASO length was reduced (20-mer to 14-mer) and 
methyl or methoxymethyl group was attached to the methylene bridge in LNA 
structure.53 The development of other bridged nucleic acid (BNA) structures, such 
as 2´-,4´-methyleneoxymethylene BNA (BNACOC)54, 2-O,4´-C-aminomethylene 
BNA (BNANC), 2´,4´-aminooxymethylene BNA and 2´,4´-(N-
methoxy)aminomethylene BNA has continued and the last three mentioned have 
appeared potential in animal models.55 In siRNA duplex, extensive modifications 
generally lead to decreased activity and the most commonly used sites for LNA 




























































Figure 9. Conformationally constrained sugar modifications. 
 
A number of DNA and RNA analogs, having phosphate or ribose moiety 
completely replaced with another structure, have been developed. These include 
peptide nucleic acid (PNA), morpholino oligonucleotides (PMO), hexitol nucleic 
acid (HNA), altritol nucleic acid (ANA), cyclohexene nucleic acid (CeNA) and 
tricyclo-DNA (tcDNA) (Figure 10).8,56-58 In antisense use, all the oligonucleotide 
analogs comprising these entities have high affinities to mRNA and enhanced 
nuclease stability, but they do not support cleavage mechanism through RNase H, 
except for CeNA-RNA duplexes, which have been reported to activate RNase H 









Figure 10. Nucleotide analogs with replaced sugar or phosphate structure. 
 
In PNAs, the sugar-phosphate backbone is replaced with a peptide-related 
structure.8,56  Besides being highly nuclease resistant, PNA provides high-affinity 
binding to complementary RNA or DNA. As uncharged molecules, PNAs seem to 
be nontoxic owing to their low affinity for proteins. However, their solubility and 
poor cellular uptake limits their potential as antisense agents. Instead, PNA has 
been utilized as cell-penetrating peptide (CPP) conjugates (Section 1.3.3.2).60,61 
Similarly CPPs have been used to facilitate the cell delivery of another uncharged 
oligomer PMO57, in which the sugar-phosphate structure is placed with a six-
membered morpholino ring and phosphoroamidate backbone. PMOs have shown 
antisense efficacy based on steric blocking in vivo and also in human clinical 
trials.10,62 Improved performance was recently reported with siRNAs that 
incorporated morpholino analogues at 3´-end of both strands.63  
 
HNA, an analog having six-membered 1,5-anhydrohexitol carbohydrate moiety, 
hybridizes strongly with RNA (prefer A-form duplex) and its 3´-OH derivative 
called ANA results in even more increased duplex stabilities.58 An HNA-gapmer 
oligonucleotide comprising a central phosphorthioate sequence has been used to 
target the mRNA of MDR1-gene playing a role in multi-drug resistance of cancer 
cells.64 Lipofectamin 2000 was used as a transfection agent. Incorporation of a few 
HNA nucleotides into siRNAs that target the mRNA of human B-Raf oncogene 
(critical for growth and survival of melanoma cells) has been reported to improve 
effectiveness and duration of action of the siRNA.65 Similar effects have been 
demonstrated for ANA-modified siRNA targeted against mRNA of MDR166 and 
also for siRNA incorporating one or two ceNA modifications, especially in the 
middle sections of both the sense and antisense strand.67 Part of the improved 
biological activity may be attributed to increased stability towards nucleases, 
achieved even with minimal number of substitutions. However, no clear correlation 
between activity and biostability has been detected with siRNAs incorporating 
conformational constrain and complex tc-DNA analogs.68 The most active siRNAs 
(~4-fold increase relative to native siRNA) for silencing of EGFP gene (reporter 
gene that encodes green fluorescent protein) that contained tc-DNA modifications 






Recently a flexible, acyclic and helix destabilizing RNA mimic called unlocked 
nucleobase analog (UNA, Figure 10) has been shown to reduce off-target silencing 
by siRNA without compromising on-target efficiency, when incorporated in the 
seed region of the antisense strand.69,70 At the 5´-end of the sense strand, UNA can 
block the loading of wrong strand into RISC and concomitantly improve antisense 
strand activity.70 UNA monomers were also found to be compatible with RNase H 
activity.71  
 
1.3.2.2 Modifications of nucleobases 
Nucleobases has been modified (Figure 11) mainly to increase binding affinity to 
complementary nucleic acids.8,31 This can be accomplished by enhancing stacking 
interactions or strengthening the Watson-Crick base-pairing. However, the base-
pair recognition must not be disturbed and, hence, the number of heterocyclic base 




Figure 11. Nucleobase modifications.  
 
With antisense oligomers, the pyrimidine C5 position has commonly been used as 
the site of modifications, because such substitutions generally improve affinity 
without affecting the ability to activate RNase H.31,73 These C5-analogs include 5-
methylcytosine and 5-propynyl nucleosides. However, 5-propynyl substituents 
have been found to be toxic in vivo.74 Tricyclic phenoxazine and G-clamp cytosine 
derivatives have also been shown to enhance stacking.73 
 
With siRNAs, nucleobases, such as 2´-thiouracil and pseudouracil, has been used to 
enhance potency and specificity.28,75 The most active duplexes were those having a 
high-affinity 2´-thiouracil base at the 3´-end of the antisense strand and a low-
affinity dihydrouracil base at the 3´-end of the sense strand. In general, bulky or 





substitutions compatible with RNAi have been prepared, including some atypical 
base structures like 2,4-difluorotoluyl base. Difluorotoluyl ribonucleoside cannot 
form hydrogen bonds, but it has been shown to improve the nuclease resistance in 
serum and maintain siRNA activity even at an internal position.76 
 
1.3.3 Conjugate groups for cell delivery 
Two strategies contribute to the search for chemically enhanced delivery of 
oligonucleotides.77 One is design of non-covalently assembled oligonucleotide-
complexes, in which cellular uptake is increased by various carriers. These include 
cationic lipids, dendrimers, polymers, cyclodextrins, and even carbon nanotubes. 
These applications are not discussed here in more detail. 
 
The second strategy comprises covalently bound oligonucleotide conjugates, such 
as lipophilic substituents, cell-penetrating peptides and ligands for cell surface 
receptors. In principle, stoichiometric covalently bound oligonucleotide conjugates 
can provide higher concentrations of the nucleic acid drugs compared to the non-
covalently bound complexes, in which an excess of complexing agent is generally 
required. In addition, to reach the site of action within the target cell, the nucleic 
acid needs to stay associated with its carrier during the extracellular delivery, which 
may not be the case with non-covalently bound complexes.78 On the other hand, 
covalent attachment of a bulky conjugate group to the oligonucleotide may 
influence its intracellular distribution, such as the entry to nucleus, or disturb 
hybridization to the target.77 To circumvent this, a cleavable linkage between the 
oligonucleotide and ligand has been employed.30 For example, acid labile linkages 
(e.g. -thiopropionate) are expected to be cleaved in the acidic endosome 
compartments and reducible bonds (e.g. disulfide) in the reductive cytosolic 
environment to release the intact oligonucleotide inside the cell.  
 
1.3.3.1 Lipophilic and vitamin conjugates 
The internalization of anionic oligonucleotides requires a passage through the 
hydrophobic interior of the phospholipid bilayer membrane. Therefore, conjugation 
with lipids has been employed as a possible method to facilitate oligonucleotide 
uptake.26,60,79 Besides reducing the hydrophilic nature of oligonucleotides, some 
hydrophobic ligands, such as cholesterol, can bind to lipoproteins, which are 
cholesterol carriers in blood. Consequently, cholesterol conjugate becomes 
recognized by their target cells leading to internalization by lipoprotein-mediated 
endocytosis. The cholesterol-siRNA conjugate has been shown to induce silencing 
of the apolipoprotein B mRNA (apoB encodes a protein essential for cholesterol 
metabolism) in mice liver and jejunum, which was not detected with naked 
siRNA.80 Cholesterol was conjugated to the 3´-end of the sense strand in siRNA via 
pyrrolidine linker.  
 
Other lipophilic siRNAs conjugated with long-chain fatty acids and bile acid 
(Figure 12) also bind to lipoproteins allowing siRNA uptake and gene silencing in 





hence, to the gene silencing capability. A novel mechanism for cell entry of 
lipoprotein-associated cholesterol-siRNA has been suggested. Instead of simple 
receptor-mediated endocytosis, the conjugated siRNA is argued to pass from the 
lipoprotein receptor to a separate transmembrane transporter, which mediates the 
cellular uptake. Such a transmembrane protein is Sid 1 that seems to be required for 
siRNA uptake.   
 
 
Figure 12. Structures of fatty acid and bile acid siRNA-conjugates. 
 
Cholesterol has also been attached to the 5´-end of siRNA sense strand.82,83 
According to a study on targeting p38 MAP kinase mRNA in mouse lung, 
cholesterol conjugation may extend but not increase siRNA-mediated 
knockdown.83  
 
Hydrophobic vitamin E has its own physiological transport pathway to most organs 
and one of its eight natural isomers, viz. -tocopherol has been conjugated to the 5´-
end of the antisense strand in siRNA (Figure 13a).84 The -tocopherol moiety was 
designed to be cleaved by Dicer after entering the cell, producing a mature siRNA 
against apoB mRNA. Efficient in vivo silencing was achieved in liver without 







Figure 13. Vitamin conjugates: (a) -tocopherol-bound siRNA, (b) Folate conjugated 
siRNA. 
 
Other vitamins, including fat-soluble vitamin A (retinol) and folic acid, have also 
been used as carriers for nucleic acids.85,86 In general, vitamins are described to be 
internalized through cell-surface receptors and their recognition often depends on 
interaction with binding proteins. In the case of vitamin E, binding to lipoproteins 
or other serum proteins initiates the cellular uptake.85 By contrast, vitamin A is 
probably absorbed by cells through the receptor of retinol-binding protein and 
recently, vitamin A-coupled liposomes has been used for siRNA delivery to hepatic 
stellate cells.87 Folic acid conjugations have been applied to various 
macromolecules to allow their binding to folate receptors.86 Since folate receptors 
are overexpressed in many human tumors, they can be exploited in targeted cancer 
therapies and receptor-mediated in vivo delivery to malignant cells and tissues has 
been reported with folic acid conjugated siRNA (Figure 13b).88 
 
1.3.3.2 Cell penetrating peptides 
Cell penetrating peptides (CPP) compose a large group of unrelated sequences, 
which are often positively charged and have a high content of basic amino acids 
and a length of 10-30 residues.32,60,61,89 They are able to mediate the cellular uptake 
of nucleic acids, in most cases probably through endocytosis, although the precise 
mechanism remains elusive and may depend on the case. Some of the most 
commonly used CPPs include TAT (trans-activator protein from HIV-1) peptide, 



























R8 / R9 
e.g. (RXR)4XB 
and (RXRRBR)2XB 
(A = alanine, B = -alanine, C = cysteine, F = phenylalanine, G = glycine, H = histidine, I = isoleucine, K = 
lysine (dK = D-lysine), L = leucine, M = methionine, N = asparagine, P = proline, Q = glutamine, R = 
arginine, S = serine, T = threonine, W = tryptophan, X = 6-aminohexanoic acid, Y = tyrosine) 
 
Figure 14. (a) Some commonly used cell penetrating peptides, (b) Example of arginine-
rich CPP-PMO conjugate. 
 
In early studies, TAT and Penetratin peptides were shown to improve biological 
effects when attached to 5´-ends of antisense oligonucleotides via disulfide 
bond.60,90 However, it seems that inefficient escape from endocytic vesicles 
generally limits the function of some antisense CPP-conjugates and most of the 
endosomolytic agents used in vitro studies are too toxic for in vivo applications.89,91  
This has led to chemical modification of standard CPPs and few representative 
examples are shown in Figure 14a from CPP families of Penetratin and poly-
arginine.61 Also strategies such as co-treatment with endosome-disrupting peptides 
and photochemical internalization have been explored. 
 
CPPs have most extensively been used for the delivery of neutral oligonucleotide 
analogs such as PMO (morpholino oligonucleotides) and PNA (peptide nucleic 
acid) showing in several studies good effectiveness in modulation of the RNA 
splicing processes via steric blocking.60-62 Recently, hereditary muscle disease 
(Duchenne muscular dystrophy (DMD)), which is caused by a mutation in the 
dystrophin gene was approached with PMO conjugate of arginine-rich CPP (i.e. 
(RXRRBR)2XB) linked through a stable amide bond (Figure 14b).92 Systemic 
delivery was reported to restore dystrophin protein levels to almost normal in the 
cardiac and skeletal muscles in mice. In general, incorporation of structures like 6-
aminohexanoic acid (X) and -alanine (B) into oligoarginine peptides has been 
reported to increase serum stability and to generate higher antisense activities of 
CPP-PMO, which even exceed those seen with TAT-peptide.93 It has been 
hypothesized that although X/B-containing conjugates enter cells less efficiently 
than oligoarginines, a greater ability to escape from endosomes/lysosomes could 
count for the good activity of these arginine-rich CPPs.94 PNA internalizing 
peptides (Pip) have been derived from Penetratin CPP, and their PNA conjugates 
have shown enhanced serum-stability and exhibited strong activities for splicing 





siRNA having TAT peptide conjugated to the 3´-end of the antisense strand via a 
sulfosuccinimidyl-4-(p-maleimidophenyl)-butyrate linker, was reported to show 
substantial improvement in delivery and downregulation of the target protein.96 
Similarly Penetratin peptide attached via a disulfide linkage to the 5´-terminus of 
the sense strand showed effects on primary mammalian neuronal cells.97 In another 
study, Penetratin and TAT conjugated siRNAs, however, showed only very modest 
gene-silencing.83 Penetratin-conjugate also triggered an innate immune response, 
while unconjugated Penetratin and TAT peptides caused uncharacterized effects 
upon gene expression. The latter observation emphasizes the importance of the 
conjugate purity on assessing the siRNA activities.  
 
Besides being covalently bound to CPP, the negatively-charged molecules ASO 
and siRNA may benefit from non-covalent strategies (not covered here), being able 
to interact with positively charged CPPs and, hence, forming complexes with a 
positive net charge.61 
 
1.3.3.3 PEG conjugates 
Polyethylene glycols (PEG, Figure 15a) are amphipathic and non-ionic polymers, 
which has been conjugated to oligonucleotides to serve as ligands themselves or as 
linkers for other conjugate groups.26,79 PEG-oligonucleotide conjugates are 
expected to facilitate transport and they have been reported to improve nuclease 
stability and pharmacokinetics. PEG conjugates are often complexed with cationic 
polymers or peptides to form colloidal nanoparticles, so-called polyelectrolyte 
complex micelles (PEC micelles, Figure 15b) useful as delivery vehicles.30 The 
main route of cellular entry is believed to be absorptive endocytosis, unless specific 
ligands that facilitate receptor-mediated endocytosis are present. In vivo, targeted 
delivery to tumor cells has been demonstrated with PEC micelles consisting of 
polyethylenimine (PEI) and pegylated oligonucleotide conjugates of folic acid98 or 











Figure 15. (a) Structure of PEG-oligonucleotide, (b) formation of PEC micelles and (c) 
PEG-PLL(DMMAn)-Mel-siRNA conjugate. (See abbreviations for amino acids in Figure 
14) 
 
Recently, siRNA was covalently incorporated into a pH- and redox-responsive 
polymer via a disulfide bond (Figure 15 c).100 Covalent binding was used to 
overcome the risk of complex dissociation in extracellular environment. The 
polymer was attached to the 5´- end of the sense strand. It consisted of three 
different moieties: polylysine (PLL) for binding and protection of RNA, PEG for 
increasing solubility and improving pharmacokinetics, and the lytic peptide melittin 
for endosomal release. Melittin was masked with dimethylmaleic anhydride 
(DMMA) and exposed upon endolysosomal acidification. This siRNA conjugate 
was reported to exhibit high biocompatibility and efficient gene silencing in vitro, 
but toxicity studies revealed problems in vivo.   
 
1.3.3.4 Cationic and polyamine conjugates 
Introduction of positive charges into oligonucleotides favors hybridization with 
nucleic acid targets and possibly enhances cellular permeation, because of reduced 
electrostatic repulsion.26,77 Bearing this in mind, many covalently-linked polyamine 
and cationic oligonucleotide conjugates have been prepared but their effects on 
cellular uptake have not been broadly assessed. One potential cationic group is 
guanidinium function, which is adopted from arginine residue and has been shown 
to improve cellular uptake while introduced on the nucleobases or on the backbone 
(Figure 16). As guanidinium group is highly basic (pKa 12.5), the modified 
oligonucleotides should remain protonated under a wider range of pH than their 
amino analogues. Fully or partially modified guanidine PNAs were reported to be 
taken up by several cell lines by a mechanism that referred to direct 
translocation.101,102 However, other studies with DNA analogues incorporating 5-
[(6-guanidinohexylcarbamoyl)methyl]-2´-deoxyuridine nucleosides103 or 3´-





mechanism. In vivo splice-correction efficiency has been demonstrated with 
guanidinium dendritic scaffold covalently-linked to a PMO.105  
 
 
Figure 16. Guanidino oligonucleotide analogues. 
 
Spermine conjugated siRNAs (Figure 17a) were shown to enter human cells and 
result in gene silencing in submicromolar concentration range.106 Altogether 30 
spermines were conjugated to the 5´-end of the siRNA sense strand to achieve the 
desired charge ratio. In other studies, 2´-polyamine modified nucleotides (Figure 
17b), bearing either a lysylaminohexyl group, a succinyl-linked spermine ligand or 
its longer pentaamine version, were incorporated into oligonucleotides and reported 





Figure 17. (a) The structure of spermine-siRNA and (b) polyamine conjugations to 2´-





Aminoglycosides (examples in Figure 18) comprise a very versatile and unique 
group of cationic ligands possessing characteristics exploitable in antisense 
approaches.23,109-112 They contain hydrophilic amino-modified sugars and due to 
their polycationic nature under physiological conditions, they show considerable 
affinity to nucleic acids. The well-known activity of aminoglycosides as antibiotics 
is based on inhibition of the bacterial protein synthesis by binding to the ribosomal 
RNA. Besides ability to bind RNA and inhibit its function, aminoglycosides show 
potential for chemical cleavage of RNA. Their conjugation to oligonucleotides can 
also enhance the cellular uptake and neomycin has been shown to assist the cationic 
lipid-mediated delivery of oligonucleotides.113 Enhanced uptake has also been 
observed with neamine conjugated PNA targeting HIV-1 TAR RNA (see Section 
1.5.1).110 Neutral carbohydrate ligands exploited for enhancement of delivery are 
presented in next section 1.3.3.5.   
 
 
Figure 18. Structures of some aminoglycosides. 
 
1.3.3.5 Glycoconjugates 
Both carbohydrate-protein and carbohydrate-carbohydrate interactions play a 
central role in cellular recognition.114-116 This is allowed by the wide structural 
diversity of carbohydrates and can be utilized in targeted delivery of nucleic acid 
drugs decorated with sugars. Lectins are carbohydrate binding proteins that exist in 
most living organisms and interact with sugars in a highly specific manner. 
Extracellular lectins recognize carbohydrate epitopes of other cells and pathogens 
whereas intracellular lectins take part in processing of glycoconjugates and quality 
control.116 The broad range of different kind of lectins can be grouped in families 
characterized by similar sequences and structural organization.117  
 
According to the basic idea of glycotargeting, cell-membrane anchored lectin can 
recognize the carbohydrate residue of an oligonucleotide drug and induce the 
internalization by receptor-mediated endocytosis.118 Since the binding of a single 





high-affinity binding requires multiple simultaneous interactions with sugars.117,119 
This phenomenon is known as a “cluster glycoside effect”, i.e. the presence of 
multivalent ligands is able to enhance binding beyond what could be expected due 
to the increase in local sugar concentration alone. In nature, the multivalency is 
often employed to ensure high specificity and thus, to ensure the correct 
functioning of cells. Consequently, an efficient glycotargeting strategy depends on 
the development of multivalent glycoconjugates having proper spatial 
arrangements.118,120 Along with this, it has been recognized that the length of the 
spacer, separating the carbohydrate moieties and nucleic acid, needs to be sufficient 
for optimal binding affinity to lectins. Many synthetic approaches for covalently 
bound oligonucleotide conjugates have already been reported but only a few have 
been tested for their biological activity. 
 
Most extensively investigated target for oligonucleotide glycoconjugates is the 
galactose-specific asialoglycoprotein receptor, which belongs to the so-called C-
type lectin family and is located on hepatocytes (cells of the main liver tissue).117,118 
Trivalent N-acetylgalactosamine residue (Figure 19a) has been conjugated to 
methylphosphonate and phosphorotioate oligonucleotides showing enhanced 
cellular uptake to the animal (mice) liver in vivo experiments.121,122 Similarly, 
tetravalent galactoside cluster (Figure 19b) markedly improved the hepatic uptake 
(from 19 % to 77 % of the injected dose in rats) after derivatization and specific 
accumulation of the antisense oligonucleotide into parenchymal liver cells was 
reported to increase almost 60-fold.123  
 
Figure 19. Glycoconjugates for asialoglycoprotein receptor-mediated delivery: (a) 
trivalent N-acetylgalactosamine residue, (b) tetravalent galactoside cluster, (c) 
galactosylated PEG-ASO conjugate, (d) lactosylated PEG-siRNA conjugate, (e) 





The asialoglycoprotein receptor has also been targeted with galactosylated PEG-
conjugate attached to the 3´-end of an oligonucleotide phosphorothioate (Figure 
19c).124 Enhanced delivery to hepatocytes was reported in vivo via receptor-
mediated endocytosis, although this conjugate carried only one sugar residue. In 
another study, the 5´-end of the sense strand in siRNA was conjugated with 
lactosylated PEG moiety (Figure 19d) and complexed with poly(L-lysine) to form 
PEC micelles.125,126 These micelles, entrapping targeting siRNA for RecQL1 
helicase (ReQ helicase family is involved in maintaining genomic stability), 
showed significant and prolonged growth inhibition of the spheroids formed from 
human hepatocarcinoma cells.126 Both sugar-PEG residues (Figure 19c,d) were 
attached to the oligonucleotides using a -thiopropionate linker, which is expected 
to be cleaved in the acidic environment of the endosomal compartment. siRNA has 
also been conjugated through the 3´-end of the sense strand with galactose- or 
(mannose-6-phosphate)-PEG ligand via a cleavable disulfide bond (Figure 19e).127 
The conjugates were used for targeted delivery to hepatocytes and hepatic stellate 
cells, respectively, and they resulted in gene silencing in vitro.  
 
The structure-function relationship of the glycoside clusters has been evaluated by 
measuring their affinities towards carbohydrate-binding proteins.128-130 For 
example, the affinities of galactose clusters with linear, calixarene or antenna type 
structures towards the lectins PA-IL (Pseudomonas aeruginosa lectin) and RCA 
120 (Ricinus communis agglutinin) were assessed by using microarray 
techniques.130 It was concluded that the spatial arrangement was more important 
than the number of galactose moieties: a linear trivalent residue showed better 
binding affinities than antenna and calixarene presentations with ten, four or eight 
galactose moieties, respectively (Figure 20). This behavior was more pronounced 
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Facilitation of cellular surface absorption and uptake through GLUT receptor-
mediated endocytosis has been studied with 5´-terminal glucose-DNA conjugates 
(most potent ones are shown in Figure 21).131 Glucose is an essential substrate for 
cell metabolism and glucose transporter proteins are found in most mammalian cell 
membranes. Conjugates having longer spacers (15-18 atom distances) for the 
glucose moiety were reported to be internalized better than those having a short 
linker (4 atom distance). However, the high multivalency seemed to hinder the 
cellular uptake as the conjugates with a tetravalent glucose presentation did not 
show improved delivery. 
 
 
Figure 21. Glucose-DNA conjugates. 
 
1.4 Oligonucleotide conjugation chemistry 
1.4.1 Automated oligonucleotide chain assembly 
The chemical synthesis of DNA/RNA oligomers is usually carried out on a solid 
support using an automated synthesizer (Figure 22).132 According to the basic 
principle, the 3´-hydroxy group of the 3´-terminal nucleoside residue is covalently 
attached to a solid support via a cleavable linker, i.e. most often via a succinyl 
linker to amino-modified CPG (Controlled Pore Glass) support. This is followed by 
a stepwise addition of nucleotide residues to the 5'-terminus of the growing chain 
by appropriate coupling chemistry. Phosphoramidite coupling promoted by a 
tetrazole-based activator is the most commonly applied strategy. H-Phosphonate 
chemistry, using e.g. pivaloyl chloride as an activator, is another useful method for 
oligonucleotide synthesis. In both approaches, the cycle starts with the removal of 
the acid-labile 5´-O-(4,4´-dimethoxytrityl) protecting group from the support-
bound nucleoside. The exposed 5´-hydroxy function is then coupled with the 
incoming monomeric nucleotide bearing a 3´-(2-cyanoethyl-N,N-
diisopropylphosphoramidite) or 3´-(H-phophonate) group. The principal difference 
between the two coupling protocols is that in phosphoramidite strategy, the 
oxidation step to produce phosphate from the initially formed phosphite is repeated 
in every cycle, whereas the H-phosphonates are oxidized in a single step after 
completion of the chain assembly. Capping step is required to terminate chain 
elongation in the case of failed coupling and, thus, to prevent the formation of 
oligomers with an internal base deletion. The nucleobase moieties are usually 
protected with base-labile acyl groups that are stable during oligonucleotide 
synthesis, but are removed during the final ammonolytic treatment. Along with the 
base protections, also phosphate moieties (in the case of phosphoramidite) become 




















































































Pr = protecting group
DMTr = 4´,4-dimethoxytrityl
X = H (DNA) or
OR (e.g. protected RNA)
Y = succinyl modified CPG
5. Ammonolysis:





removal of base protections
and release from the support  
Figure 22. The principle of solid-supported oligonucleotide synthesis by the 
phosphoramidite and the H-phosphonate strategy. 
 
In addition to natural nucleosidic building blocks, it is likewise possible to insert 
modified monomers into the chain by phosphoramidite or H-phosphonate coupling. 
These include nucleosidic derivatives having modified sugar, base or phosphate 
moieties as well as non-nucleosidic analogues and many illustrative examples are 
presented in section 1.3.  
 
1.4.2 Conjugation strategies 
Oligonucleotides can be conjugated either at the termini or inside the sequence.132-
134 Since the oligonucleotide is usually assembled in the 3´  5´ direction, the 
conjugation to the 5´-end is quite straightforward on using a phosphoramidite or H-
phosphonate derived from the conjugate group. However, other type of 
functionalities can be attached as well via the 5´-hydroxy group. Conjugation to 3´-
end is accomplished using modified supports. Another possibility is to assemble the 
oligonucleotide chain in an inverse manner from the 5´-end to the 3´-end, in which 





building block needs to have an exposable hydroxyl group for chain elongation in 
addition to the phosphoramidite or H-phosphonate functionality. 
 
In general, the conjugate groups can be attached to the oligonucleotide either 
directly using pre-fabricated building blocks or through a reactive moiety that is 
kept protected during the chain assembly and after exposure subjected to post-
synthetic conjugation (Figure 23).134 There are multiple reasons that make the post-
synthetic approach practical and universal. First of all, the preparation of ready-
made building blocks with all required functional moieties at one molecule can be a 
complex task and each compound must be separately phosphitylated. The stepwise 
character of the post-synthetic method simplifies the synthetic routes and enhances 
flexibility. Less variable chemical conditions that may complicate protecting group 
strategies during the oligonucleotide synthesis are needed. Finally, the conjugate 
groups tend to be rather bulky and their presence at the coupling step can hamper 
the coupling.  
 
 
Figure 23. Schematic representation of conjugation strategies applied to attach two 
different ligands at intrachain positions: (a) ready-made building blocks are used and after 
chain assembly, the oligonucleotide conjugate is ready without further derivatization or (b) 
building blocks bear functional groups that are post-synthetically conjugated. In the 
example illustrated here, the same conjugation chemistry is applied for both conjugate 
groups and therefore reactive group Y is converted to X prior the second functionalization.  
 
The post-synthetic introduction of the conjugate groups into oligonucleotides falls 
in two main categories: solution- and solid-phase conjugation.79,132 The major 
advantage of solid-phase methods compared to the conjugation in solution is easier 
purification. The insoluble carrier enables the removal of reagents and unbound 
side products by simple filtration and washing. Consequently, reagents can be used 
in a large excess, which helps to drive the reactions to completion. Conjugations 
made in solution usually require chromatographic purifications before and after 
each conjugation step, whereas the solid-supported oligomer product is purified 





made in solution and the solution-phase approach can really be a method of choice 
in many instances.133 For example, if the conjugate group is not stable during 
ammonolytic treatment or is otherwise incompatible with the applied strategy, it 
can be introduced to the oligonucleotide in a final solution-made step.  
 
1.4.3 Covalent linkages for conjugate groups 
Different kinds of reactive functionalities have been introduced into 
oligonucleotides enabling a wide variety of chemistry. In principle, many of these 
post-synthetic conjugation methods can be applied both on a solid support and in 
solution. A brief overview is given to some of the most commonly used approaches 





























































































































































Figure 24. Commonly used conjugation chemistries and covalent linkages.134 Residues R1 
and R2 refer to either oligonucleotide or conjugate group side. 
 
Amino groups have been used to form amide (A) or thiourea (B) bonds by a 
reaction with an activated carboxylic and isothiocyanate groups, respectively. 
Aldehyde function can be derivatized with an amino, hydrazine and aminooxy 
groups to produce imine, hydrazine (D) and oxime (E, F) linkages, among which 
the imine is further reduced to amine bond (C).  
 
The reaction of thiol group with an active thiol (G), maleimide (H) or 1,2-
aminothiol (I) group has also been exploited in oligonucleotide conjugations. 
Especially, the disulfide bond has been used in antisense approaches, because it is 
unstable in the cytosol due to the reducing environment of intracellular 
compartments and it, hence, enables the release of oligomer after cellular uptake. 
An acid-labile -thiopropionate linkage, which is a -substituted thioether, has also 





hydrolyzed under acidic conditions present at endosome compartments.124-126 A 
biodegradable bond between oligonucleotide and ligand group can be particularly 
advantageous in the case of very large conjugates such as those creating PEC-
nanoparticles (Section 1.3.3.3). Among the sulfur containing linkages, also the 
thiazolidine is prone to hydrolysis at acidic pH.134 Finally, the so-called native 
ligation (J) is another sulfur-based method, which involves the coupling reaction 
between an activated thioester and an -aminothiol.  
 
Recently the “click chemistry” has received a vast interest in oligonucleotide 
conjugations. The concept of click chemistry refers to modular reactions that show 
high efficiency, yield and stereospecificity.135 The examples include Diels-Alder 
(K), Huisgen dipolar cycloadditions (L) and Staudinger ligations (M). The Huisgen 
1,3-dipolar cycloaddition reaction has particularly found wide scope in synthetic 
applications and will be discussed  in more detail in the Result and Discussion part. 
 
1.5 Antisense targeting of RNA secondary structures 
RNA folds through base pairing interactions into secondary structures composed of 
duplexes and intramolecular stem-loop regions (hairpin).33,136-138 These secondary 
structures (Figure 25) are induced by mismatched and unpaired bases, which cause 
a perturbation of the fully complementary A-form RNA·RNA helix. In hierarchical 
pathway, the primary sequence dictates the type of secondary structure formed, 
which in turn leads to formation of possible tertiary structure. In cell biology, the 
folding process provides stability for RNA and structural motifs, which are 
recognized by a number of ligands including proteins, nucleic acids and 
ribonucleoproteins that participate in the intermediary metabolism and activities of 
RNA species. 
 
Figure 25. The general classes of RNA secondary structure.137 
 
Since the RNA duplex is not a viable target for antisense binding, an effective 





RNA segments within mRNA accessible for hybridization.9,33 These sites locate 
usually at the terminal end, internal loops, joint sequences, hairpins and bulges. 
Similarly efficient siRNA silencing is influenced by local characteristics of the 
target RNA and a correspondence between the accessibility for antisense 
oligonucleotides and siRNAs has been demonstrated.19,139 Ultimately, it is a 
question about how well an exterior antisense molecule can invade to the target 
RNA region and reorganize the secondary structure. The formation of a ligand-




Here, the RNA-ligand (complex) refers to all conformations that may result from 
the binding. The corresponding dissociation constant Kd describes quantitatively 
the affinity between a ligand and a target RNA and is defined:140 
 
         
     
 
 
However, the development of any truly reliable algorithm for computational 
prediction of a single secondary structure of RNA is problematic due to RNA´s 
adaptive behavior.9,136 It is likely that RNA conformation alters significantly as it 
bounds to various ligands and thus accessibility to a particular RNA site can be 
changed. There are several experimental methods which are employed for 
evaluation of ligand-RNA binding, at least as long as small molecule ligands are 
concerned.23 These include approaches such as mass-spectrometry-assisted 
screening, fluorescence spectroscopy using fluorescently labeled RNAs or ligands 
and gel shift assay, which fractionalizes molecules on the basis of different 
mobilities through the gel medium. Also UV-denaturation profiles (Section 3.1.4) 
or CD spectra can be used to assess hybridization affinities of oligonucleotides. 
Finally, NMR-spectroscopy has been established as a reliable method for structural 
determinations.141,142 From the methods listed above, NMR is an exceptional 
technique to follow invasion process of the antisense oligonucleotide ligand to the 
folded RNA as it allows detection and quantification of dynamic equilibria between 
coexisting nucleic acid structures. Especially 19F-NMR employing 19F-labeled 
oligonucleotides143-148 has many advantages for such analysis and will be 
introduced and explored more detailed in Results and Discussion (Section 3.2). 
 
1.5.1 Case study – Antisense approaches targeting HIV TAR 
Human immunodeficiency virus (HIV) possesses a remarkable ability to adapt and 
evade both host immune responses and suppression by antiviral drugs, because of 
its rapid genetic diversity and the capability to undergo mutations.149 Thus, despite 
of the current drugs, the need for new HIV therapies that are less prone to the 
generation of resistant viral strains persist. For the purpose, several antisense-based 






One attractive antisense target is the highly conserved trans-activating response 
element TAR (Figure 26), which is a specific bulged RNA hairpin loop located at 
the 5´-end of all HIV mRNAs.150 TAR region is recognized by the HIV trans-
activator protein TAT, which binding to the TAR-element is essential for efficient 
viral transcription and replication. Thus, inhibition of the TAT-TAR interaction by 
targeting the TAR-element has been explored as a potential anti-HIV strategy.  
 
 
Figure 26. Secondary structure of HIV-1 TAR-element. 
 
A steric block mechanism has been evaluated with modified antisense 
oligonucleotides incorporating 2´-O-methyl, N3´-P5´-phosphoramidate and PNA 
analogues and also with chimeric oligomers containing 2´-O-Me/LNA units.51,151,152 
Targeting the stem-loop region, these 16 or 12 long oligomers were reported in 
vitro to efficiently and sequence-specifically inhibit the reverse transcription (the 
process by which the RNA-virus can reverse-transcribe their RNA genomes into 
DNA, which is then integrated into the host genome and replicated along with it). 
Compared to the solely 2´-O-methyl modified oligomers, the addition of LNA units 
(optimally 40-50 %) was shown to enhance cellular uptake using cationic agents as 
well as nuclear uptake and increase binding to the target RNA.51 Shorter than 12 
mer OMe/LNA oligonucleotides were inactive.  
 
The cell delivery issues of anti-TAR oligomers have been addressed with cell-
penetrating peptides including Transportan, Penetratin, R6-Penetratin and TAT-
peptide.153-155 Promising results in cell internalization and inhibition of HIV-1 
replication were reported with 16mer disulfide-linked PNA-CPP conjugates (Figure 
27).154 Cellular uptake of the PNA-Penetratin conjugate was most efficient, while 
inhibition ability was highest for PNA-Transportan-27. In addition to antiviral 
activity, the conjugates with Penetratin, Transportan-21 (more than Transportan-
27) and TAT-peptide were importantly shown to act as an anti-HIV virucidal-
agents capable of inactivating or destroying viruses, which could essentially have 









The cellular uptake of anti-TAR PNA has also been improved by conjugation with 
neamine (Figure 27) which is a constituent of aminoglycoside antibiotics such as 
neomycin B (see Section 1.3.3.4) and enhances the solubility of PNA.110 In 
addition to the inhibition of HIV-1 replication in vitro, neamine-PNA conjugate 
was shown to exhibit RNA cleavage activity for its target site in TAR.  
 
Targeting of the TAR regions with RNAi-based mechanism has met a mixed 
success.150 While some inhibition of HIV replication was observed using 21-mer 
siRNA duplex in cell culture,156 it has been suggested that the siRNA activities are 
affected by too tight secondary structure of TAR.157 Recently, it was reported that 
RNAi directed against TAR can inhibit HIV replication, but resistant viral strains 
were recovered in long term cell cultures.149 However, none of the altered strains 
carried a mutation at the target site consistent with a view of TAR as a conserved 
sequence. Instead, evidence was given that several strains had promoter mutations 
that indirectly compensated for the RNAi by upregulating viral transcription. 
Consequently, combinatorial RNAi against various RNA targets of the HIV has 
been suggested.158 Modified siRNA containing conformationally locked 2´,4´-
carbocyclic ribo-thymidine (jcLNA) monomers at both ends of the antisense strand 
(Figure 28) was reported to have enhance siRNA efficiency in addition to increased 




Figure 28. Structure of jcLNA modification and the targeted region within TAR. 




2. AIMS OF THE THESIS 
Antisense technology holds a tremendous potential for drug discovery based on 
selective gene-silencing. However, nucleic acids are not optimal drug-like 
molecules and both single-stranded antisense oligonucleotides and double-stranded 
siRNAs encounter many biological barriers before they can reach the target RNA 
in the cell cytoplasm or nucleus. To overcome these barriers, oligonucleotides are 
chemically modified and conjugated in various ways. The aim of the present thesis 
is to provide an efficient conjugation strategy for oligonucleotides based on click 
chemistry. The concept of generality is on high importance for synthesis strategy 
since the applicable conjugations comprise a vast repertoire of chemically different 
residues. This criterion is well met with the orthogonal-nature of click reaction 
referring to the Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddition between azide 
and alkyne.  
 
As particularly poor cell delivery limits the development of antisense therapeutics, 
oligonucleotide conjugations that allow efficient cellular uptake and provide cell-
type organ specificity are desired. One such approach is to decorate 
oligonucleotides with carbohydrates playing role in cell recognition. The sense 
strand of siRNA can serve as a scaffold to which the lecting binding sugar ligands 
are tethered at appropriate distances.  For this purpose, the present study 
demonstrates the preparation of several oligonucleotides having glycoconjugates at 
their intrachain positions. A prerequisite for this approach is that the siRNA duplex 
formation is not severely retarded.  
 
Finally, the thesis approaches a fundamental RNA invasion process by which the 
antisense oligonucleotide is able to bind its target and reorganize the secondary 
structure of the folded mRNA. As the strand invasion process itself is well known, 
the means through which to follow its progress in detail are rather limited. 19F-
NMR spectroscopy offers a novel tool to study RNA conformations and the 
methodology for monitoring of invasion of short oligonucleotides to the RNA 
secondary structure model is described.  
 
In more detail the aims of the thesis may be summarized as follows: 
- Preparation of the branched building blocks applicable for the click 
conjugation strategy and for the attachment of residues at intrachain 
positions.   
- Assembly of the modified oligonucleotides and their post-synthetic click-
conjugation on a solid support or in solution with different kind of ligands 
including carbohydrates. 
- Assessment of the hybridization properties concerning the conjugates and 
thus, evaluation of their feasibility for antisense use. 









3. RESULTS AND DISCUSSION  
3.1 Click conjugation of oligonucleotides 
3.1.1 Nucleosidic building blocks for click conjugations 
The concept of click chemistry was evolved to provide simple methods to join 
together organic molecules in high yields under mild conditions and in the presence 
of a diverse range of functional groups.135,160 Sharpless and co-workers have 
identified a number of reactions that meet the criteria for click chemistry, but 
especially the Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddition between azide and 
alkyne161,162 has emerged as a most widely applied approach (Figure 29). This 
particular click reaction has many potential features for the conjugation of nucleic 
acids.160,163 The presence of azides or alkynes does not usually disturb the 
biophysical properties of nucleic acids and they are almost entirely unreactive 
towards the functional groups normally encountered in nature. Thus they react only 
with each other forming a triazole unit, which is extremely stable and non-toxic. 
However, the efficiency of the reaction along with the regioselectivity to produce 
solely the 1,4-regioisomer (and not 1,5-regioisomer) requires the use of copper(I) 
catalysis, which can cause radical induced damage within the oligonucleotide 
chain. To overcome this problem, copper(I)-stabilizing ligands such as TBTA 




Figure 29. The Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddition to produce a 1,4-
triazole and the structure of copper(I)-stabilizing TBTA-ligand. 
 
To apply a post-synthetic click conjugation strategy on oligonucleotides, four 
different 4´- and 2´-modified building blocks 1-4 bearing azido or alkynyl moiety 
are introduced by the present study (Figure 30).I-III These monomers can be 
incorporated into oligonucleotide chain using either phosphoramidite or H-
phosphonate coupling chemistry on an automated DNA/RNA synthesizer (Section 
1.4.1). Together these modified nucleotides, i.e. 4´-C-azidomethylthymidine 3´-(H-
phosphonate) (1), 4´-C-[N,N-di(4-pentyn-1-yl)aminomethyl]thymidine 3´-
phosphoramidite (2), 4´-C-[N-methyl-N-(4-pentyn-1-yl)aminomethyl]thymidine 3´-
phosphoramidite (3) and 2´-O-[(2-azidoethoxy)methyl]cytidine 3´-(H-phosphonate) 
(4) enable the exploitation of the click conjugation on both ways, in other words to 
have azido function present either on the oligonucleotide or ligand side. Nucleoside 
2 bearing two 4-pentyn-1-yl groups is designed for high density functionalization 
of modified oligonucleotides whereas nucleosides 1, 3 and 4 allow one-armed 
conjugations. 























2: R = 4-pentyn-1-yl































Figure 30. Monomers for oligonucleotide click-conjugation. 
 
Previous studies have shown that ribose 2´- and 4´-positions facing the minor 
groove upon hybridization are potential for modifications.39,49,165-173 
Oligonucleotides incorporating 2´- or 4´-modified nucleosides have been reported 
to form rather stable double helices with unmodified complementary sequences and 
they are less prone to enzymatic degradation than their unmodified counterparts. In 
addition, 4´-modified nucleosides have shown compatibility with RNase H 
activity.169,174 In contrast, 2´-modified nucleosides, which adopt A-type helical 
geometry do not support RNase H mechanism (Section 1.3.2.1).39 
 
Monomers 1 and 4 were incorporated into the oligonucleotide by the H-
phosphonate chemistry since intramolecular Staudinger reaction between the azido 
and phosphoramidite group makes the phosphoramidite building block highly 
unstable. We attempted the oligonucleotide synthesis using 4´-C-
azidomethylthymidine 3´-phosphoramidite but although the building block could 
still be isolated with fast work-up, it was not stable enough for chain assembly. 
Sekine et al. has previously reported that the reaction of 2-azido-2´-deoxyadenosine 
(6) with diethyl-N,N-diisopropylphosphoramidite gave phosphazide intermediate 
(7) of the Staudinger reaction, which was then converted into final 
iminophosphorane product 8 (Scheme 1).175 Nevertheless, as shown by the present 
study,I the presence of an azido group in the growing solid-supported 
oligonucleotide chain does not disturb the phosphoramidite coupling of subsequent 
monomers and, hence, the Staudinger reaction seems to interfere with only by a 
genuinely intramolecular mechanism.  





Scheme 1. Staudinger reaction between azido group and phosphoramidite derivative.175 
 
Phosphoramidite approach is the most applied method for oligonucleotide synthesis 
on solid support but H-phosphonate methodology is also a viable alternative.176 On 
the basis of this work, however, it seemed that structural changes to the standard 
nucleosides were less tolerated by the H-phosphonate protocol which resulted in 
decreased coupling yields with monomers 1 and 4 (Section 3.1.3.1) while coupling 
efficiency was well retained on using phosphoramidite monomers 2, 3 and 5.I-III 
Although protocol adjustments may partly restore the coupling efficiency, it was 
concluded that the phosphoramidite approach is preferred when available. 
  
Besides having azido group present at a building block itself, it can be introduced 
post-synthetically to the oligonucleotide. For this purpose, 2´-O-[(2-
bromoethoxy)methyl]cytidine 3´-phosphoramidite (5) monomer was synthesized 
and used as a precursor for the corresponding azido derivative. The feasibility of 
the displacement reaction from bromo to azido group on a solid support has been 
established in recent studies177,178 and the method avoids the usage of nucleoside H-
phosphonate. Importantly, when bromo and azido group bearing monomers are 
both used in the oligonucleotide synthesis, they allow an attachment of two 
different ligands to the oligomer. This type of conjugation strategy is outlined in 
Section 1.4.2 (Figure 23) and demonstrated with 2´-modified monomers 4 and 5.III 
 
3.1.1.1 Synthesis of 4´-C-azido and alkynyl modified thymidine   
            monomers 
Previously, a synthesis route for 4´-C-hydroxymethylthymidine has been developed 
starting from thymidine.168,179,180 Accordingly, the 5´-hydroxyl group of 3´-
protected thymidine is oxidized to aldehyde and the 4´-C-hydroxymethyl moiety is 
obtained by aldol condensation with formaldehyde followed by Cannizzaro 
reduction. In the present study, 3´-O-(4,4´-dimethoxytrityl)-4´-C-
hydroxymethylthymidine (11) was synthesized in overall yield of 74% (For 
synthesis procedures see Experimental).I Prior to the introduction of the 4´-branch, 




5´-OH of the thymidine (9) was temporarily protected by benzoyl group, which was 
removed after completion of 3´-O-(4,4´-dimethoxytrityl) protection ( 10). 
Noteworthy, the employment of 3´-O-4,4´-dimethoxytrityl protection168 being fully 
stable under alkaline conditions of aldol-cannizaro step is recommended over 3´-O-
TBDMS protection, which has also been previously applied for the purpose.167  
 
4´-C-Azidomethylthymidine has also been previously synthesized,181 but only in 
low yield via mesylation of 4´-C-hydroxymethyl-3´-O-TBDMS-thymidine and 
subsequent treatment of the mixture of the mono- and di-mesylated products with 
LiN3. Since this route includes tricky chromatographic separations of regioisomers, 
the method that exploits O2,5´-anhydronucleoside formation182 in making a 
difference between the two primary hydroxyl functions seemed more feasible. 
Accordingly,I the primary hydroxyl groups of compound 11 were converted to their 
triflates to obtain 12. Deprotonation of the thymine base resulted in cyclization to 
O2,5´-anhydro nucleoside, from which the remaining triflate group could be 
displaced with an azide ion, giving the desired 4´-C-azidomethyl group (13). The 
O2,5´-anhydro linkage was hydrolyzed with sodium hydroxide and the resulting 
nucleoside 4´-C-azidomethyl-3´-O-DMTr-thymidine (14) was converted to its 5´-
O-DMTr-isomer (15) and finally to the corresponding 3´-(H-phosphonate) (1). 
Altogether, the synthesis of building block 1 is efficient and the overall yield from 
thymidine is 42 %. 
 
 
Scheme 2. Reagents: (i) BzCl, pyridine; (ii) DMTrCl, pyridine; (iii) NaOMe,  MeOH; (iv) 
DCC, TFA, pyridine, DMSO; (v) CH2O, aq NaOH (2.0 mol L-1), 1,4-dioxane; (vi) Tf2O, 
CH2Cl2, pyridine; (vii) NaH, NaN3,  DMF,  pyridine;  (viii)  aq  NaOH  (2.0  mol  L-1), 1,4-
dioxane; (ix) 80 % AcOH; (x) DMTrCl, pyridine; (xi) diphenyl H-phosphonate, pyridine; 
(xii) Et3N, H2O. 
 
Because the azido group can be easily converted to amino group by Staudinger 
reaction, it allows further functionalization and a route to 4´-C-alkyne derivatives. 
Accordingly,II 4´-C-aminomethyl-3´-O-(4,4´-dimethoxytrityl)thymidine (16) was 
obtained by the reaction of compound 14 with triphenylphosphine and water 
(Scheme 3). Compound 16 was then subjected to reductive alkylation in the 




presence of NaBH3CN under acidic conditions. On using 2 equiv of 4-pentynal, 4´-
C-[N,N-di(4-pentyn-1-yl)aminomethyl]thymidine (17) was obtained. 4´-C-[N-
Methyl-N-(4-pentyn-1-yl)aminomethyl]thymidine (19) was, in turn, prepared by 
two consecutive alkylation steps. Reaction with 1 equiv of 4-pentynal gave 4´-C-
[N-(4-pentyn-1-yl)aminomethyl]thymidine (18), which was then N-methylated with 
paraformaldehyde. After the reductive alkylations, the 3´-O-4,4´-dimethoxytrityl 
group was removed with 80% acetic acid. Compounds 17 and 19 were then 
converted to 5´-O-(4,4´-dimethoxytrityl) ethers (20, 21) and phosphitylated to 
phosphoramidites 2 and 3.  
 
 
Scheme 3. Reagents:  (i)  PPh3,  H2O, NH3 (aq), THF; (ii) 4-pentynal (1 or 2 eq), 
NaBH3CN, AcOH, MeOH; (iii) paraformaldehyde, NaBH3CN, AcOH, MeOH; (iv) 
DMTrCl, pyridine; (v) 2-cyanoethyl N,N-diisopropylphosphoramidochloridite, Et3N, 
CH2Cl2. 
 
There are some general observations concerning the synthesis of 4´-C-derivatives 
that should be noted.I First of all, the 3´-hydroxy group must be masked before 
conversion of the hydroxyl function in 4´-C-hydroxymethyl group into a better 
leaving group. The carbon atom of this group is surprisingly prone to nucleophilic 
attack of a neighboring hydroxyl group: a four-membered ring is easily formed by 
an attack of either the 5´- or 3´-OH. For example, the oxetane product 23 was the 
only product obtained when displacement of the tosyl group from 5´-O-(4,4´-
dimethotrityl)-4´-C-tosyloxymethylthymidine (22) with azide ion was attempted 
(Scheme 4, see Experimental). In addition, the efforts to prepare 4´-C-
propargyloxymethyl or 4´-C-pentenyloxymethyl compounds were unsuccessful as 
O2,5´-anhydro nucleosides bearing 4´-C-propargyloxymethyl (24) or 4´-C-
pentenyloxymethyl (25) group resulted in oxetane product 26 when treated with 
NaOH solution.  






Scheme 4. Easy formation of an oxetane by-product. 
 
3.1.1.2 Synthesis of 2´-O-modified cytidine monomers 
The synthesis of 2´-O-(2-bromoethoxy)methyl (27a) and 2´-O-(2-
azidoethoxy)methyl (27b) substituted cytidine nucleosides bearing 3´,5´-O-
(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl) protections has been described 
earlier.183-186 According to an “O-glycosylation method”, 3´,5´-O-(1,1,3,3-
tetraisopropyldisiloxane-1,3-diyl)-N4-benzoylcytidine was treated with (2-
bromoethoxy)methyl acetate in the presence of tin tetrachloride at -12 C. 
Nucleoside 27a was isolated in 88% yield and conversion to the corresponding 2´-
O-(2-azidoethoxy)methyl derivative (27b) by displacement of the bromo 
substituent with NaN3 in DMF was virtually quantitative. To carry on the synthesis 
of 2´-modified building blocks (27a,b) bearing azido or bromo functions, the 3',5'-
cyclic silyl protecting group was removed with Bu4NF in THF and the 5´-OH of 
the deprotected nucleosides (28a,b) was protected with a 4,4´-dimethoxytrityl to 
obtain 29a,b (Scheme 5).III Finally, 29a and 29b were converted to 3´-(2-
cyanoethyl-N,N-diisopropylphosphoramidite) (5) and 3´-(H-phosphonate) (4), 
respectively. 
 





Scheme 5. Reagents:  (i)  Bu4NF, THF; (ii) DMTrCl, pyridine; (iii) diphenyl H-
phosphonate, pyridine; (iv) Et3N,  H2O; (v) 2-cyanoethyl N,N-



















3.1.2 Conjugate groups for click conjugations 
For the click conjugations of the oligonucleotides, alkynyl and azido functionalized 
ligands were synthesized (Figure 31).I-III They included derivatives of mannose (30, 




Figure 31. Prepared alkynyl and azido functionalized ligands. 
 
3.1.2.1 Synthesis of alkynyl bearing ligands 
The alkynyl-derivatized ligands (30, 32, 33, 35) were synthesized as outlined in 
Scheme 6.I,III Fully acetylated propargyl -D-mannopyranoside (30)I and -D-
galactopyranose (32)187 were prepared from the commercially available 
peracetylated -D-mannopyranose (38) and -D-galactopyranose (39) by boron 
trifluoride etherate promoted glycosidation188 with propargyl alcohol. 
 
Trifluoroacetylated N-[4-(aminomethyl)benzyl]-4-pentynamide (33) was 
synthesized starting from the commercially available 1,4-phenylenedimethanamine 
(40).I One of the two amino groups was protected with a 4-monomethoxytrityl 
group and the other one was acylated with 4-pentynoic acid by DCC activation. 
The acid-labile trityl protection was finally changed to a base-labile trifluoroacetyl 
protection, removable by the conventional ammonolysis used for release and 
deprotection of the oligonucleotide conjugate.  
 
Neamine tetrahydrochloride (43) was obtained by methanolysis of commercially 
available neomycin B trisulfate.189 The primary 6´-amino group of neamine (43) 




was selectively acylated with succinimidyl 4-pentynoate.I To make this neamine 
derivative easier to handle and purify, the amino groups were trifluoroacetylated 
and the hydroxyl groups acetylated, and the product was purified at this stage. 
Owing to exceptionally difficult acetylation of the 5-hydroxy of neamine, a mixture 
of compounds 44 and 45 was obtained. Product 35 was received after removal of 
acetyl-protecting groups with methoxide ion catalyzed transesterification in MeOH 
under which conditions Tfa-amides are stable. The acetyl groups were removed at 
this stage to prevent O N-acyl migration when the amino groups are exposed 




Scheme 6. Reagents: (i) propargyl alcohol, BF3·Et2O, CH2Cl2; (ii) MMTrCl, dioxane, (iii) 
aq NaOH (10 % m/v); (iv) 4-pentynoic anhydride (from: 4-pentynoic acid, DCC, dioxane), 
pyridine,  DMAP;  (v)  TFA,  CH2Cl2, MeOH; (vi) TfaOMe, MeOH, Et3N; (vii) 
succinimidyl 4-pentynoate (from: 4-pentynoic acid, N-hydroxysuccinimide, DCC, 
dioxane), water, dioxane, Et3N; (viii) Ac2O, pyridine; (ix) NaOMe, MeOH.  
 
3.1.2.2 Synthesis of azido bearing ligands 
The azido-functionalized ligands (31, 34, 36, 37) used in the click conjugation were 
synthesized as outlined in Scheme 7.II The preparation of mannose-derived ligand, 
methyl 2,3,4-tri-O-acetyl-6-azido-6-deoxy- -D-mannopyranoside (31) has been 
reported previously.190 Accordingly, the overall yield of 67% was received after 
tosylation and azidation of the 6´-hydroxy group of methyl -D-mannopyranoside 
(46) and consecutive acetylation to the product 31. 
 
N-[4-(Azidomethyl)benzyl]-2,2,2-trifluoroacetamide (34) was synthesized starting 
from N-(4-methoxytrityl)-1,4-phenylenedimethanamine (41), which can be 




azidated by the Cu2+-catalyzed diazo transfer reaction described in literature191. The 
acid-labile trityl protection of the product (47) was changed to a base-labile 
trifluoroacetyl protection, removable by the conventional ammonolysis used for the 
release and deprotection of support-bound oligonucleotides.II 
 
Paromamine trihydrochloride (48) was obtained by acidic hydrolysis of 
commercially available paromomycin sulfate.192 After trifluoroacetylation of the 
amino groups, the primary 6´-hydroxyl group was protected as a 4,4´-
dimethoxytrityl ether (50) and the remaining hydroxyl functions were acetylated.II 
The 6´-position was then detritylated, sulfonylated and subjected to azidation. 
Since the azidation gave poor yields on using mesyl esters as a starting material, 
conversion of the 6´-hydroxyl group to a triflate was attempted. The conventional 
treatment with triflic anhydride in the presence of pyridine, however, yielded a 6´-
pyridinium salt instead of the desired product. Replacement of pyridine by less 
nucleophilic DBU then provided the desired triflate, which was azidated to product 
53 in 52% overall yield. This was finally deacetylated by methoxide ion catalyzed 
transesterification in methanol to obtain product 36, applicable to postsynthetic 
conjugation of the alkynylated oligonucleotides. 5´´-Azido-1,3,2´,6´,2´´´,6´´´-hexa-
N-trifluoroacetylneomycin (37) was synthesized starting from neomycin trisulfate 
(54) according to the same protocol as described for the paromamine derivative 36 
above.  





Scheme 7. Reagents: (i) TsCl, pyridine; (ii) NaN3, DMF; (iii) Ac2O, DMAP, pyridine; (iv) 
TfN3, K2CO3, CuSO4, H2O, MeOH, CH2Cl2; (v) 3% DCA, CH2Cl2, MeOH; (vi) TfaOMe, 
Et3N, MeOH; (vii) DMTrCl, pyridine; (viii) Tf2O,  10%  DBU  in  MeCN,  CH2Cl2; (ix) 









3.1.3 Oligonucleotide synthesis and click conjugation  
3.1.3.1 Oligonucleotide assembly 
One to three modified nucleosidic units (1-5) were incorporated into the middle 
section of a 15-mer oligonucleotide on an automated DNA/RNA synthesizer.I-III 
Conventional phosphoramidite chemistry was applied for the chain assembly, 
except for the introduction of the azido-functionalized building blocks (1, 4) that 
had to be coupled as H-phosphonates. Thus, a combined protocol including both 
the phosphoramidite and H-phosphonate couplings was generated for the 
synthesizer. The oligomers were assembled on a CPG-succinyl-nucleoside support 
apart from oligonucleotides 60-63 containing 4´-C-alkynyl modified monomers in 
which case a Q-linker loaded CPG support was used. 4´-C-Alkynyl modified 
oligonucleotides did not withstand solid-supported click conjugation as long as 
their phosphate groups were 2-cyanoethyl protected, but a chain cleavage took 
place at a site of the modified monomer. Q-Linker modified CPG support enabled 
the removal of the cyanoethyl protections by DBU promoted -elimination on a 
solid support (Section 3.1.3.2.2). Table 1 summarizes the prepared oligonucleotides 
(58-65). 4´-C-Modified monomers (1-3) substituted thymidines in 5´-d(CAT CTG 
GTT CTA CGA)-3´ and 2´-O-modified monomers (4, 5) replaced cytidines in 
otherwise fully 2´-O-methyl modified oligoribonucleotides 5´-r2´-O-Me(CAU CUG 
GUU CUA CGA)-3´.  
 
Table 1. Prepared oligonucleotides incorporation modified monomer 1-5.  
Used monomer Prepared oligonucleotide 
1 5´-d(CAT CTG GTT1CTA CGA)-3´ (58) 
 5´-d(CAT C T1G GT T1 C T1A CGA)-3´ (59) 
2 5´-d(CAT CTG GT T2 CTA CGA)-3´ (60) 
 5´-d(CAT C T2G GTT C T2A CGA)-3´ (61) 
3 5´-d(CAT CTG GT T3 CTA CGA)-3´ (62) 
 5´-d(CAT C T3G GTT C T3A CGA)-3´ (63) 
4 and 5 5´-r2´-O-Me(CAU T4UG GUU T5UA CGA)-3´ (64) 
 5´-r2´-O-Me(CAU T5UG GUU T4UA T5GA)-3´ (65) 
 
For phosphoramidite building blocks, i.e. 4´-C-[N,N-di(4-pentyn-1-
yl)aminomethyl]- thymidine (2), 4´-C-[N-methyl-N-(4-pentyn-1-
yl)aminomethyl]thymidine (3) and  2´-O-[(2-bromoethoxy)methyl]cytidine (5) 3´-
phosphoramidite, standard phosphoramidite coupling chemistry with 
benzylthiotetratzole activator was applied, except that a prolonged coupling time of 
10 min (typical for RNA) and an extra detritylation step for monomer 5 was used. 
All modified monomers were used at the concentration of 0.13 mol L-1 in dry 
MeCN. On the basis of DMTr-cation assay, the coupling yields for the 4´-C-
modified nucleotides were 97% and for the 2´-O-modified nucleotide 99%.  




In the case of H-phosphonate building blocks, i.e. 4´-C-azidomethylthymidine (1) 
and 2´-O-[(2-azidoethoxy)methyl]cytidine (4) 3´-(H-phosphonate), the coupling 
yields were 90% and 85%, respectively. The H-phosphonate coupling protocol for 
the synthesizer was generated on the basis of previous reports.193,194 A prolonged 
coupling time (550-750 s) provided some improvements in efficiency. Pivaloyl 
chloride and adamantane carbonyl chloride were both tested as a condensing agent 
giving similar results. Both of them were dissolved in a 1:1 mixture of MeCN and 
pyridine to obtain a concentration of 100 mmol L-1. Nucleoside 3´-(H-
phosphonates) (1, 4, TEA salts) were used as a 35 mmol L-1 solution 
(MeCN/pyridine (1:1, v/v)). Since a mixed H-phosphonate and phosphoramidite 
method could be applied instead of mere H-phosphonate coupling, unmodified and 
commercially available 2´-deoxy or 2´-O-methyl A, G, C and T / U monomers 
were coupled as phosphoramidites. After the oligonucleotide assembly, the 
support-bound material was removed from the synthesizer and oxidized with iodine 
(0.1 mol L-1) in wet pyridine (98:2, v/v) at room temperature for 1 h because the 
oxidation step used in phosphoramidite couplings is inefficient to oxidise H-
phosphonates. 
 
3.1.3.2 Click conjugations  
All the click conjugations between modified oligonucleotides and ligands were 
performed using a mixture of copper (II) sulfate and sodium ascorbate as the 
reducing agent in the presence of Cu(I)-stabilizing TBTA.I-III The reactions on a 
solid support and in solution followed the same protocol: The ligands were used as 
a 50 mmol L-1 solution in MeOH (except 25 mmol L-1 solution was used for the 
less soluble aminoglycoside ligand 35) and added to the oligonucleotides in 
amounts of 10-15 equiv per azido or alkynyl group. After that, CuSO4 and TBTA-
ligand were added as a 25 mmol L-1 solution in a 12:3:1 (v/v/v) mixture of water, 
DMSO and 2-butanol using 5-7.5 equiv per azido or alkynyl group. Finally, sodium 
ascorbate (10-15 equiv / azido or alkynyl group) as 0.1 mol L-1 aqueous solution 
was added. A reaction time of 5 h at room temperature was adequate. All the click 
reactions proceeded virtually quantitatively, as also reported previously for click 
derivatization on a solid-support or in solution.160,195,196  
 
3.1.3.2.1 Conjugation of 4´-C-azido modified oligonucleotides 
After chain assembly, oligodeoxyribonucleotides 58 and 59 were conjugated with 
alkyne-derivatized ligands 30, 33 and 35 by click chemistry.I Conjugations were 
performed either on the CPG-support or in solution. Scheme 8 outlines the 
procedure in the solution. Essentially the same chemistry was applied on a solid 
support. 


























































































69: For R, see 66





Scheme 8. Derivatization of oligonucleotides 58 and 59 by click chemistry.  
 
Standard ammonolysis (33 % aq NH3, 55 ºC, overnight) was carried out to release 
oligonucleotides from the support and to remove the protections from base 
moieties, phosphodiester linkages and conjugate groups. The advantage of the 
solid-supported synthesis is that only one ammonolytic treatment is required. By 
contrast, when the conjugation is carried out in the solution, the deprotection of the 
conjugate groups introduced requires a second ammonolysis after the click 
reaction. In principle, unprotected conjugate groups could have been used for 
conjugation, but in particular with amino groups containing ligands, it is safer to 
use protections to minimize the interactions with copper ion. The conjugates (66-
70) were then purified by RP-HPLC and their identity was verified by ESI-MS.  
The purity of the oligonucleotide conjugates was additionally checked by capillary 
electrophoresis. These studies quite unexpectedly revealed that when the click 
conjugations were performed on a solid support using amino group containing 
ligands, the conjugates obtained after RP-HPLC purification still gave two peaks in 
electropherograms. In addition, their melting temperature curves were slightly 
biphasic, lending further support for the occurrence of the conjugates as two 




isomers that had the same molecular mass (in ESI-MS only one set of signals, m/z, 
was detected) and could not be separated by HPLC. This problem was not 
encountered in solid supported conjugation with mannose ligand. Furthermore, 
when the conjugations were carried out in solution and the products were 
precipitated with EtOH, this anomality in behavior disappeared: the product was 
elecrophoretically homogeneous and exhibited normal sigmoid melting curves. 
Accordingly, some caution seems to be needed on applying click conjugation to 
ligands that offer good coordination sites, such as amino groups, for copper ions, in 
spite of the fact that the groups are kept protected during the actual cycloaddition 
reaction. 
 
Another peculiarity concerning the electropherograms of the crude conjugate 
products is also worth mentioning. Albeit the solid support was thoroughly washed 
after the click reaction, the capillary electrophoretic studies of the crude mixtures 
revealed existence of an additional complex that was not seen by RP-HPLC. This 
species appeared as a wide peak after the signal of the desired conjugate. Possibly 
the oligonucleotide conjugate remained partly associated with the TBTA ligand or 
its Cu(I) complex. Although this marked impurity could not be detected in RP-
HPLC purification, it entirely removed it, verified by electropherogram. When the 
click reaction was carried out in solution, the elctropherogram of the crude product 
showed only the broad signal of the unidentified associate discussed above. After 
precipitation of the oligonucleotide conjugate with EtOH, the signals of both the 
desired conjugate (67 in Figure 32) and the unidentified associate appeared, but 




Figure 32. Electropherogram of the crude product (67)  of  the  click  reaction  of  
oligonucleotide 58 with ligand 33 in solution. 
 
3.1.3.2.2 Conjugation of 4´-C-alkynyl modified oligonucleotides 
Click chemistry was applied to attach azido-derivatized ligands 31, 34, 36 and 37 to 
the oligodeoxyribonucleotide backbone of 60-63.II However, it was noticed that 
these 4´-C-alkynyl modified oligonucleotides did not withstand solid-supported 




click conjugation as long as their phosphate groups were 2-cyanoethyl protected, 
but a chain cleavage took place leaving the modified monomer attached to the 5´-
terminus of the support-bound oligonucleotide. By contrast, the 4-pentyn-1-yl 
functionalized oligonucleotides that had not been subjected to the conditions of 
click reaction could be isolated in intact form by conventional ammonolysis.  
 
To carry out the click reaction on a solid-support, the 2-cyanoethyl groups had to 
be removed prior to the click reaction, which was achieved by treatment with 10% 
DBU in MeCN (5-8 min). Since the succinyl linker is not fully compatible with the 
DBU treatment, but undergoes a premature cleavage via succinimide formation197, 
all the conjugate syntheses were carried out on a commercially available Q-linker 
loaded CPG support198. After exposure of the internucleosidic linkages as 
phosphodiesters, the azido-functionalized ligands 31, 34, 36 and 37 were attached 
by the click reaction and the conjugates were deprotected and released from the 





31, 34, 36 or 37
60: R1 = 4-pentyn-1-yl































71: R2 = L1
72: R2 = Me
R1
Tmod = 4´-C-modified T
Pr = base protecting groups
CNE = 2-cyanoethyl protecting groups
5´-d(CAT CTG GTTmod CTA CGA)Pr&CNE

















































74: R2 = L2

























Scheme 9. Synthesis of the conjugated oligodeoxyribonucleotides containing one 4´-C-
modified monomer. 






The crude products (71-80, see Table 3) were purified by RP-HPLC and their 
identity was verified by ESI-MS. Figure 33 shows representative examples of the 
RP-HPLC traces of the crude oligonucleotides 76 (1 neomycin ligand), 77 
(4 mannose ligand) and 80 (2 paromamine ligand) and the homogeneous products 
after purification. In each case the desired conjugate was clearly the main product. 
 
 
(A)        Crude 80                 Crude 77 
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Figure 33. RP HPLC traces of the crude (A) and purified (B) oligonucleotide conjugates 
76, 77 and 80. (Conditions: 0% to 50% MeCN in 0.1 mol L-1 TEAA (aq) buffer over 60 
min, flow rate 1 mL min-1) 
 
With 4´-C-[N,N-di(4-pentyn-1-yl)aminomethyl]thymidine and 4´-C-[N-methyl-N-
(4-pentyn-1-yl)aminomethyl]thymidine monomers (2, 3), capillary electrophoresis, 
HPLC and ESI-MS data all indicated the presence of only one pure conjugate for 
each oligonucleotide. Accordingly, all conjugations could be conveniently made on 
a solid support without complications unlike what was seen in the case of solid-
supported click conjugation of oligonucleotides containing the 4´-C-
azidomethylthymidine monomers. 




3.1.3.2.3 Conjugation of 2´-O-azidoalkyl and bromoalkyl modified   
                oligonucleotides 
2´-O-Methyl oligoribonucleotides 64 and 65 containing both bromo and azido 
functionalities within their chain were applied in a conjugation strategy that 
enabled the attachment of two different ligands to the oligomers.III Accordingly, the 
support-bound oligonucleotides were subjected to two consecutive conjugations 
with alkynyl-derivatized monosaccharides. The first sugar was introduced by the 
Cu(I) promoted click reaction with mannose-ligand 30 and the second by azidation 
of the 2-bromoethoxy group of monomer 5 followed by another click reaction, this 
time with galactose derivative 32 (Scheme 10). Both tetramethylguanidinium 
azide199 (TMGA/NaI/DMF, 65 °C) or less soluble NaN3 (NaN3/NaI/DMF, 65 °C) 
could be used as a source of azide ion as also previously demonstrated.177,178  
 
 
Scheme 10. Solid-supported introduction of two different sugar ligands into 2´-positions 
within a 2´-O-Me-oligoribonucleotide (81). 
 
The oligonucleotide conjugates obtained (81 and 82) were deprotected and released 
from the support by standard ammonolysis (33% aq NH3, 55 °C, overnight). The 
crude products were purified by RP-HPLC and their identity was verified by ESI-
MS. Figure 34 shows the HPLC traces of the crude conjugates and the 
homogeneity of the products after purification. 
 
 



















































Figure 34. RP HPLC traces of the crude and purified oligonucleotide glycoconjugates 81 
and 82, respectively. (Conditions: 0 to 50 % MeCN in 0.1 mol L-1 TEAA buffer over 60 
min, flow rate 1 mL min-1) 
 
3.1.4 Melting temperature studies of the oligonucleotide conjugates 
The introduction of conjugate groups in an oligonucleotide may more or less alter 
its hybridization properties compared to the unmodified sequence. These changes 
in binding affinity are assessed by melting temperature (Tm) studies.200 The Tm 
value based on the thermal denaturation of the oligonucleotide duplex, refers to the 
temperature at which a half of the nucleic acid double helix has dissociated into 
single strands (Figure 35). The process can be monitored by UV-spectroscopy, 
since the UV-absorbance increases upon the denaturation of double-stranded 
molecule; a phenomenon known as hypochromic effect. When the absorbance is 
plotted against temperature, a sigmoidal melting curve is obtained and the Tm of the 





Figure 35. Thermal denaturation of nucleic acids followed by UV- spectroscopy. 




In the present study, the influence of the 2´- and 4´-conjugations on the duplex 
stability was evaluated with three different ligand-types, including neutral 
carbohydrate ligands (mannose and galactose), a p-aminomethylbenzene-derived 
ligand and aminoglycoside ligands.I-III The melting temperatures of the 
oligonucleotide conjugates 66-82 with their complementary DNA or 2´-O-methyl 
RNA sequences were measured at pH 7 at the ionic strength of 0.1 and 1.0 mol L-1. 
The lower salt concentration represents the physiological conditions and the high 
salt content was used to elucidate the significance of electrostatic interactions 
induced by the conjugate groups. At a high ionic strength, the electrostatic 
repulsion between negatively charged sugar-phosphate backbones is diminished 
and consequently, the influence resulting from charged functional groups of ligands 
becomes less prominent. Amino groups, for example, are usually positively 
charged at neutral pH and their neutralizing effect can often be seen as an increased 
duplex stability, which is more profound at a low ionic strength.  
 
Mannose and galactose ligands were chosen to test the feasibility of the 2´- and 4´-
glycoconjugations since the carbohydrates offer a possible way to improve the 
delivery and targeting of siRNA and antisense oligonucleotides (Section 1.3.3.5). 
Previously, the main attention has been paid to preparation of oligonucleotide 
conjugates bearing a multi-armed glycocluster at either terminus of the 
chain.130,177,178,201-204 However, as far as glycotargeting of siRNA is concerned, 
another approach appears possible, viz. decoration of the sense strand with sugars. 
A prerequisite for this approach is that the sugar ligands do not markedly 
destabilize the duplex. In other words, the sense strand is aimed at serving as a 
scaffold to which the lectin-binding sugar ligands are tethered at appropriate 
distances throughout the molecule. Since the carrier is simultaneously able to 
hybridize with the antisense strand, the latter becomes enriched at the cell surface 
and, hence, internalizated by receptor-mediated endocytosis. 
 
3.1.4.1 Hybridization properties of 4´-C-conjugates 
According to previous studies,166-171 oligonucleotides containing 4´-C-modified 
DNA monomers generally prefer hybridization towards complementary DNA over 
RNA. 4´-C-Acylthymidines,205 for example, adopt a C(2´)-endo-like conformation 
found typically in B-type DNA-DNA duplex. In the present study,I,II the amino-
group bearing conjugates (67, 68, 70, 73-76, 78-80) were found to have a similar 
preference for the complementary DNA. However, an opposite behavior was 
detected with oligonucleotides containing mannose groups (66, 69, 71, 72, 77). The 
melting temperature values for oligodeoxyribonucleotides 58-63 and their 
conjugates 66-80 with the complementary DNA and 2´-O-methyl RNA sequences 
are shown in tables 2 and 3. The results referring to the Tm values of 4´-C-azido and 
4´-C-alkynyl derived oligonucleotides are presented separately because the original 
studies were made on two different instruments using dissimilar temperature 
detection (see Experimental). Nevertheless, the temperature shifts are still 
comparable.   
 
 




Table 2. Melting experiments of the 4´-C-azido-derived oligonucleotide conjugates and 
their complementary DNA or 2´-O-Methyl-RNA sequencesa   
 
 Compl. DNA 
Tm / ºC and (  Tm / ºC) 
Compl. 2´-O-methyl RNA  
Tm / ºC and (  Tm / ºC) 
 0.1 mol L-1  
NaCl 
1.0 mol L-1 
 NaCl 
0.1 mol L-1 
 NaCl 
1.0 mol L-1 
 NaCl 
5´-CAT CTG GTT CTA CGA 55.4 65.0 57.0 68.0 
5´-CAT CTG GTBCTA CGA (58) 53.8 (-1.6) 63.3 (-1.7) 56.5 (-0.5) 67.4 (-0.6) 
5´-CAT CBG GTB CBA CGA (59) 51.5 (-3.9) 62.3(-2.7) 55.8 (-1.2) 67.4 (-0.6) 
5´-CAT CTG GTD CTA CGA (66) 53.0 (-2.4) 63.0 (-2.0) 56.8 (-0.2) 68.0 (0) 
5´-CAT CDG GTD CDA CGA (69) 50.3 (-5.1) 61.3 (-3.7) 56.2 (-0.8) 69.5 (+1.5) 
5´-CAT CTG GTE CTA CGA (67) 55.6 (+0.2) 64.7 (-0.3) 56.2 (-0.8) 67.6 (-0.4) 
5´-CAT CEG GTE CEA CGA (70) 56.4 (+1.0) 63.9 (-1.1) 55.6 (-1.4) n. m. 
5´-CAT CTG GTF CTA CGA (68) 55.8 (+0.4) 63.8 (-1.2) 55.3 (-1.7) 67.3 (-0.7) 
aIn 10 mmol L-1 potassium phosphate buffer (pH 7) containing 0.1 mol L-1 or  1.0  mol  L-1  NaCl.  The  
oligonucleotide conjugates and their cDNA or 2´-O-methyl RNA targets were used at a concentration of 2 











Table 3. Melting experiments of the 4´-C-alkynyl-derived oligonucleotide conjugates and 
their complementary DNA or 2´-O-Methyl-RNA sequencesa   
 
 Compl. DNA 
Tm / ºC and (  Tm / ºC) 
Compl. 2´-O-methyl RNA  
Tm / ºC and (  Tm / ºC) 
 0.1 mol L-1  
NaCl 
1.0 mol L-1 
 NaCl 
0.1 mol L-1 
 NaCl 
1.0 mol L-1 
 NaCl 
5´-CAT CTG GTT CTA CGA 52.8 61.9 54.1 65.0 
5´-CAT CTG GTH CTA CGA (60) 54.5 (+1.7) 61.3 (-0.6) 54.7 (+0.6) 65.1 (+0.1) 
5´-CAT CHG GTT CHA CGA (61) 52.5 (-0.3) 59.7 (-2.2) 53.0 (-1.1) 65.4 (+0.4) 
5´-CAT CTG GTI CTA CGA (62) 54.6 (+1.8) 62.5 (+0.6) 55.7 (+1.6) 66.4 (+1.4) 
5´-CAT CIG GTT CIA CGA (63) 53.5 (+0.7) 61.6 (-0.3) 52.4 (-1.7) 64.7 (-0.3) 
5´-CAT CTG GTJ CTA CGA (71)   53.8 (+1.0) 62.1 (+0.2) 54.3 (+0.2) 65.5 (+0.5) 
5´- CAT CJG GTT CJA CGA (77) 51.3 (-1.5) 59.6 (-2.3) 53.8 (-0.3) 66.1 (+1.1) 
5´-CAT CTG GTK CTA CGA (72) 54.6 (+1.8) 62.2 (+0.3) 54.6 (+0.5) 65.3 (+0.3) 
5´-CAT CTG GTL CTA CGA (73) 57.9 (+5.1) 63.7 (+1.8) 54.2 (+0.1) 64.3 (-0.7) 
5´-CAT CLG GTT CLA CGA (78) 62.0 (+9.2) 66.6 (+4.7) 56.7 (+2.6) 66.5 (+1.5) 
5´- CAT CMG GTT CMA CGA (79) 61.0 (+8.2) 66.5 (+4.6) 57.3 (+3.2) 67.1 (+2.1) 
5´- CAT CTG GTN CTA CGA (74) 57.9 (+5.1) 62.2 (+0.3) 53.2 (-0.9) 64.8(-0.2) 
5´-CAT CTG GTO CTA CGA (75) 57.8 (+5.0) 63.5 (+1.6) 54.1 (±0.0) 65.1 (+0.1) 
5´- CAT COG GTT COA CGA (80) 58.2 (+5.4) 62.8 (+0.9) 55.1 (+1.0) 65.2 (+0.2) 
5´-CAT CTG GTP CTA CGA (76) 56.1 (+3.3) 62.1 (+0.2) 52.5 (-1.6) 64.2 (-0.8) 
aIn 10 mmol L-1 potassium phosphate buffer (pH 7) containing 0.1 mol L-1 or  1.0  mol  L-1  NaCl.  The  
oligonucleotide conjugates and their cDNA or 2´-O-methyl RNA targets were used at a concentration of 2 
mol L-1.  
 
When one or three 4´-C-azidomethylthymidine monomers B were incorporated into 
an oligonucleotide (58, 59), the melting temperature of the duplexes with 
complementary DNA and 2´-O-methyl RNA sequences dropped, but less with 2´-
O-methyl RNA ( Tm/modification  -0.5 ºC) than with DNA ( Tm/modification  -
1.5 ºC). On the contrary, the 4´-C-alkynyl modified monomers H and I were better 
accommodated into the duplexes and their oligonucleotides (60-63) formed more 
stable hybrids with DNA than with 2´-O-methyl RNA. One monomer H or I 
showed even a stabilizing effect with both complementary strands, but a slight 
destabilization took place with two such monomers. 
 
Conjugates of mannose ligand 
Conjugation of the 4´-C-azidomethylthymidine units with mannopyranoside (D in 
66, 69) slightly increased the destabilization of the DNA-hybrid but, interestingly, 
hybridization with 2´-O-methyl RNA target was even slightly enhanced, in 
particular at high ionic strength.  




With 4´-C-alkynyl derived mannose conjugates (J and K in 71, 72, 77), the 
presence of a single monomer J (71) or K (72) in the DNA-hybrid increased the Tm, 
but two modified units in 77 were destabilizing. By contrast, on using a 2´-O-
methyl RNA target, the conjugate containing two J monomers and, hence, four 
mannose residues hybridized almost as well as the corresponding unmodified 15-
mer oligodeoxyribonucleotide. Actually, the destabilizing effect of two H units in 
the heteroduplex of sequence 61 was completely recovered with the conjugate 77 
containing two J monomers (Tm increased -1.1  -0.3 ºC) and the 2´-O-Me target 
became more favorable than the complementary DNA (compare Tm of -0.3 ºC to -
1.5 ºC with cDNA). At high salt concentration, the mannose conjugates formed 
slightly more stable duplexes with 2´-O-methyl RNA than the unmodified sequence 
but in the case of DNA-hybrids the high ionic content lowered the melting 
temperatures compare to the low salt concentration and the presence of two J 
monomers was clearly destabilizing. 
 
Conjugates of amino group bearing ligands 
All conjugates bearing amino groups (67, 68, 70, 73-76, 78-80) stabilized the 
duplex with DNA target. This was especially marked with 4´-C-alkynyl derived 
monomers L, M, N, O and P. With the p-aminomethylbenzene conjugates, the 
DNA-hybrids incorporating one or two L (73, 78) or M (79) monomers were 
stabilized by 4-5 ºC / modification. Towards 2´-O-methyl RNA, the stabilization 
was less prominent. The stabilization was more marked at a low ionic strength, but 
it still existed at a high ionic strength. Undoubtedly, major part of the stabilization 
results from reduced electrostatic repulsion between negatively charged sugar-
phosphate backbones and positively charged amino groups present at neutral pH.  
 
When one paromamine derived monomer, N (74) or O (75) was incorporated into 
the strand, the DNA-hybrid was stabilized by 5 ºC, but the second monomer (80) 
did not result in any extra stabilization. With 2´-O-Me RNA target, two monomers 
O were needed to achieve even a modest increase in Tm ( Tm = +1.0 ºC). Compared 
to the paromamine monomers, the neomycin group (monomer P in 76) was less 
stabilizing than the paromamine group (monomer O in 75) towards DNA, and 
towards 2´-O-Me-RNA, the effect was even destabilizing. Similarly to the p-
aminomethylphenyl ligands, the duplex stabilizing effects of the aminoglycoside 
ligands were more marked at a low ionic strength.   
 
With 4´-C-azido derived monomer E (67, 70) and F (68) the stabilization of the 
DNA-hybrid was modest and Tm was in fact decreased at a high salt concentration. 
With complementary 2´-O-methyl RNA strand, the melting temperatures were 




The hybridization properties of the 4´-modified oligonucleotides were encouraging 
particularly with the conjugates of 4´-C-alkynyl monomers 2 and 3. Evidently the 
4´-position, facing the minor groove upon hybridization, can accommodate even 
rather large molecule clusters without appreciable destabilization of the duplex. 




The results received with the mannose conjugated oligonucleotides lend some 
support for the feasibility of sugar-coated oligonucleotides as carriers of RNA-type 
oligonucleotides. It was demonstrated that the oligonucleotides containing one to 
four mannose ligands in the central part of the chain can form equally stable 
duplexes with complementary 2´-OMe RNA as the corresponding unmodified 
DNA sequence. The results with the space demanding aminoglycoside ligands 
further demonstrate the utility of 4´-modified nucleosides in glycoconjugations. In 
the case of 4´-C-alkynyl derived conjugates, all amino group bearing 
oligonucleotides stabilized the DNA DNA duplex significantly. Among them, the 
most remarkable hybridization enhancement was obtained with p-
aminomethylphenyl conjugates (73, 78, 79). Sterically more demanding 
aminoglycoside ligands (74-76, 80) stabilized the DNA DNA duplex less, but still 
notably. All conjugates bearing amino group preferred DNA over 2´-OMe RNA. 
 
Compared to 4´-C-azido derived conjugates, oligonucleotides resulting from 
conjugation of 4´-C-alkynyl modified units exhibited better hybridization 
properties. This implies that the alkyl chain of the 4´-C-(4-pentyn-1-
ylaminomethyl)thymidine monomers (2, 3) allows a more flexible alignment of the 
triazole ring and conjugate groups upon hybridization. The tertiary amino group, 
which probably is protonated under physiological conditions, further stabilizes the 
duplex formation by diminishing the electrostatic repulsion between the 
complementary chains, as evidenced by the fact that the melting temperatures 
observed for the oligonucleotides containing 4´-C-(alkynylaminomethyl)thymidine 
units (60-63) are higher than those observed for their 4´-C-azidomethylthymidine 
counterparts (58, 59).  
 
3.1.4.2 Hybridization properties of 2´-O-conjugates 
It has been shown previously that oligonucleotides bearing a -D-ribofuranosyl 
group at an intrachain 2´-O form stable complexes with RNA ( Tm = 0 °C) and 
maintain A-type helical geometry with the additional 2 -O-ribose moiety located in 
the minor groove.172,173 Consistent with these findings, the sugar ligands attached in 
the present study to 2´-O via a [2-(4-hydroxymethyl-1H-1,2,3-triazol-1-
yl)ethoxy]methyl linker only slightly destabilized the duplex.III Table 4 records the 
melting temperatures (Tm) for the duplexes of oligonucleotide conjugates 81 and 82 















Table 4. Melting temperatures for the duplexes of oligonucleotide conjugates 81 and 82 
with their complementary DNA and 2´-O-Methyl-RNA Sequencesa  
 
 Compl. DNA 
Tm / ºC and (  Tm / ºC) 
Compl. 2´-O-methyl RNA  
Tm / ºC and (  Tm / ºC) 
 0.1 mol L-1  
NaCl 
1.0 mol L-1 
 NaCl 
0.1 mol L-1 
 NaCl 
1.0 mol L-1 
 NaCl 
5´-CAU CUG GUU CUA CGA 50.1 61.7 72.0 n.m. 
5´-CAU XUG GUU YUA CGA (81) 50.6 (+0.5) 60.6 (-1.1) 71.5 (-0.5) n.m. 
5´-CAU YUG GUU XUA YGA (82) 47.0 (-3.1) 60.2 (-1.5) 68.2 (-3.8) n.m. 
 
a X = monomer 4 conjugated with  30; Y = monomer 5 conjugated with 32; n.m. = not measured (Tm was too 
high to be accurately determined). In 10 mmol L-1 potassium phosphate buffer (pH 7) containing 0.1 mol L-1 
or 1.0 mol L-1  NaCl. The oligonucleotide conjugates and their cDNA or 2´-O-methyl RNA targets were 
used at a concentration of 2 mol L-1.  
 
The sugar ligands accommodated quite well in the duplex structure. 
Oligonucleotide 81 bearing two sugar units in an intrachain position exhibited even 
a slight stabilization of the duplex with DNA target at a low ionic strength ( Tm = 
+0.5 °C) and a slight destabilization at a high ionic strength ( Tm = -1.1 °C). 
Addition of a third sugar ligand to obtain conjugate 82 resulted in a moderate 
destabilization even at a low ionic strength ( Tm = -3.1). At high ionic strength the 
destabilization was less prominent ( Tm = -1.5 °C). With 2´-O-Me RNA target, two 
sugar ligands within conjugate 81 were similarly well tolerated ( Tm = -0.5 °C), but 
with the 82, containing three sugars, Tm again dropped significantly ( Tm = -3.8 
°C). A tentative explanation for the marked destabilizing influence of the third 
sugar, especially at a low ionic strength, is that two of the sugars are rather close to 
each other within conjugate 82, viz. in positions 10 and 13. 
 
3.2 Characterization of RNA invasion by 19F NMR spectroscopy 
Invasion is a fundamental process of RNA, in which a weak stem region is 
denatured by an exterior single strand resulting in a reorganized secondary 
structure. This well-known process is applied e.g. in the antisense approach 
(Section 1.5),136 but the means with which to follow its progress are rather limited. 
Methods employing thermal UV-denaturation profiles or fluorescence or CD 
spectra are more likely to fail in observation of invasion, since what happens is a 
conversion of double helix to another double helix. Gel shift assay in principle 
allows determination of the equilibrium constants for this kind of a chain invasion, 
but it may skew the equilibrium between weakly interacting species. Instead, 19F 
NMR spectroscopy appears potential for such an analysis.206,143-148 It has been 
previously utilized in several related studies, including identification of site-
specific RNA binders,145 detection of DNA duplex formation,147 characterization of 
HIV-2 TAR RNA146 and, finally, quantification of hairpin/hairpin143,207 and 
duplex/hairpin148 equilibria of self-complementary DNA/RNAs. The latter is an 




excellent example of how a temperature-dependent shift of 19F resonances can be 
used for the analysis of dynamic equilibria of co-existing intra- and intermolecular 
secondary structures. Compared to that, RNA invasion represents an even more 
complex reaction system and the present study offers the first example of the 
applicability of 19F NMR spectroscopy for elucidation of the course of such a 
process.IV Accordingly, invasion of 2 -O-methyl oligoribonucleotides into a 19F-
labeled HIV-1 TAR RNA model and the temperature-dependent behavior of the 
complexes obtained were examined. Additionally, the influence of a known TAR 
ligand, viz. neomycin B,208 on the invasion was demonstrated. 
 
The fluorine atom has a single naturally occurring isotope (19F) with a spin of ½ 
and its resonance is expected to give distinct signal in different molecular 
environments.206 Compared to 1H-NMR spectroscopy, which also is applicable for 
the purpose, the fluorine chemical shifts range is wider (~50-fold larger than that of 
1H) and the shifts are more sensitive to local environmental changes. In addition, 
the process may be monitored by user-friendly way without marked NMR 
specialization and without need of a high quality NMR-instrument. Finally, the 
nonexistence of fluorine atoms in RNA enables the measurements without 
background signal interference, but as a consequence, the method requires fluorine-
labeling of the oligonucleotide. 
 
Various fluorine probes incorporated into nucleic acids have been employed in 19F-
NMR spectroscopy including 2 -deoxy-2 -fluoronucleosides,143,145 5-[4,4,4,-
trifluoro-3,3-bis(trifluoromethyl)but-1-ynyl]-2 -deoxyuridine,147 5-fluoropyrimidine 
nucleotides144,146,207 and 2,4-difluorotoluene nucleosides148 (Figure 36). An 
important requirement for the fluorine probe is that it should not cause any 
substantial deviations from the nativity of the biopolymer. As an alternative 
strategy, the potential of external probes has been proposed. Their applicability for 













3.2.1 Preparation of the 19F-labeled RNA target 
5-[4,4,4-Trifluoro-3,3-bis(trifluoromethyl)but-1-ynyl]-2 -deoxyuridine probe was 
selected as a fluorine-label and incorporated into the HIV-1 TAR RNA model in 
place of the uridine nucleoside within the tetranucleotide stem between the loop 
and the bulge of the native TAR structure (Figure 37).IV The selected probe bears 
nine magnetically equivalent fluorine atoms, which allows rapid measurements at a 
micromolar RNA concentration. Additionally, the fluorine atoms of this probe are 
not magnetically coupled to protons, which provides resonance signals as singlets 
without fluorine-proton decoupling. HIV-1 TAR element is a widely used target for 























(Bold letters refer to 2´-O-methyl
ribonucleotides, rest to ribonucleotides)  
 
Figure 37. Sturcture of the prepared 19F-labeled HIV-1 TAR RNA model.  
 
5’-O-(4,4´-Dimethoxytrityl)-5-[4,4,4-trifluoro-3,3-bis(trifluoromethyl)but-1-ynyl]-
2’-deoxyuridine phosphoramidite (86) monomer used in the oligonucleotide 
synthesis of 19F-labeled TAR model was prepared as described earlier (Scheme 
11).147 Starting from 5-iodo-2’-deoxyuridine (83) the building block 86 was 
received with Sonogashira reaction, followed by tritylation and phosphitylation. 




Scheme 11. Reagents: (i) 4,4,4-trifluoro-3,3-bis(trifluoromethyl)butyne, Pd(PPh3)4, DMF, 
CuI, diisopropylethylamine; (ii) DMTrCl, DMAP, pyridine; (iii) 2-cyanoethyl N,N-
diisopropylphosphoramidochloridite, Et3N, CH2Cl2. 
 
The oligoribonucleotide assembly of the HIV-1 TAR model was performed on an 
automated synthesizer applying standard RNA coupling protocol 
(benzylthiotetratzole activator) for the commercially available 2´-O-TOM protected 

































and 2’-O-methyl ribonucleoside phosphoramidite monomers. Two 2 -O-methyl 
ribonucleotides were inserted to both ends of the chain to increase the stability of 
/5 -stem region and to protect the model against degradation by exonucleases. As 
previously reported,147 the fluorine label 5’-O-(4,4´-dimethoxytrityl)-5-[4,4,4-
trifluoro-3,3-bis(trifluoromethyl)but-1-ynyl]-2’-deoxyuridine phosphoramidite (86) 
was coupled, however, manually since the automatic incorporation proved 
ineffective. Accordingly, the phosphoramidite (0.2 mol L-1, 250 L, 5.0 equiv) and 
the activator (0.25 mol L-1, 250 L) in MeCN were added to the solid-supported 5’-
CUCUGGC resin (bold letters refer to protected 2’-O-methyl nucleotides and the 
rest to 2’-O-TOM-protected nucleotides) and the suspension was mixed for 15 min 
at 25°C under nitrogen. The coupling was carried out twice. After oxidation and 
capping steps which were also performed manually, the oligonucleotide synthesis 
with commercial monomers was continued on the synthesizer. On the basis of 
DMTr-cation assay, the manual coupling of 86 was quantitative. The 
oligoribonucleotide was released from the resin by the usual ammonolysis protocol 
and the 2’-O-TOM protections were removed by consecutive treatments with 
Et3N•3HF (60:16, v/v, 65 °C, 1h)  in DMSO and 0.1 mol L-1 aqueous NaOAc (65 
°C, 1h). The crude TAR model was purified by RP HPLC and the authenticity of 
the product was verified by ESI-MS. 
 
The influence of the 19F-label to the native TAR structure was evaluated by UV- 
spectroscopy comparing Tm-values of the labeled HIV-1 TAR to that of the non-
labeled (Figure 38, 25 mM NaH2PO4 buffer, pH 6.5).IV Respectively, Tm-values of 
60.7 °C and 63.4 °C were received. As the label decreased melting temperature by 
2.7 °C, it undoubtedly facilitated invasion to the TAR model. If the results are 
directly interpreted to the behavior of native TAR, this destabilization should be 












Figure 38. UV-melting curves of 19F-labeled TAR model and native TAR. 
 
 




3.2.2 19F NMR spectroscopy studies 
The critical parameters for determining the effects on the spectrum upon ligand 
binding to target nucleic acid are the chemical shift differences resulting from 
changes in environment of the fluorine probe and the rate of transfer between free 
and complexed (RNA + ligand) states.140 If the binding of a ligand is strong, the 
equilibrium between the complexed and the free state is slow in the NMR time 
scale and two distinct signals are obtained. Consequently, Kd may be determined by 
comparing relative peak areas. By contrast, when the binding of a ligand is 
relatively weak, the exchange between bound and free forms will be rapid. This 
leads to averaged signal and Kd may be accurately determined (if the well-behaved 
fast-exchange ligand-RNA interaction is obtained) by following the signal shift. 
Intermediate exchange case results in line broadening and this type of signal 
indicates the presence of dynamic processes.   
 
Sample preparation for the 19F-NMR measurements and the details of the 
instrumental and experimental protocols are presented in the Experimental part. 
The concentration used for TAR oligonucleotide was 20 mol  L-1 and the 
measurements were performed in 25 mmol L-1 NaH2PO4-buffer (pH 6.5) in D2O-
H2O (1:5 v/v).  
 
3.2.2.1 Melting temperature determination of TAR model 
19F-NMR spectroscopy was previously used in melting temperature determinations 
of hairpin and double helix structures incorporating 2,4-difluorotoluene nucleoside 
in the place of uridine.148 Upon stepwise increase of temperature, the 19F-NMR 
spectra reflected the melting behavior. In the case of monomolecular hairpin model, 
the melting process occurred in the fast exchange regime on the NMR time scale 
giving averaged signal. When the shifts in 19F resonances were plotted against 
temperature, a sigmoidal curve was received and the obtained Tm was reported to 
correlate with that measured by UV-spectroscopy. In contrast, the melting behavior 
of a bimolecular duplex showed slow exchange regime on the NMR time scale and 
two sets of signals were observed. Plotting the fraction of single strand against 
temperature, afforded the Tm value. 
 
Similarly, the applicability of the 19F-probe used in the present study was evaluated 
for the melting temperature determination of TAR model (see A B in Figure 
39).IV At 25 °C, the probe gave one sharp 19F resonance signal at 66.32 ppm, 
which upon heating underwent a linear temperature-dependent passive shift to 
downfield (traces i iv in Figure 39a and slope 0.014 ppm K 1 in Figure 39b; note 
the reference signal with the same value). On approaching the Tm value (v vii in 
Figure 39a), this signal was broadened and a new broad signal appeared 0.4 ppm 
upfield. The latter signal most likely referred to the denatured form B of the TAR 
model. As the two signals were observed simultaneously and no averaging 
occurred, it meant that the equilibration between the double-helical (A) and single-
stranded (B) forms of the TAR model was slow on the NMR time scale below the 
melting temperature. Upon further heating, the signals shifted closer to each other, 



















being almost equal sized at 60 °C ( Tm, vii in Figure 39a). Coalescence to the broad 
signal at 66.32 ppm was observed at 66 °C (vi in Figure 39a). According to the 
shift, this signal referred to a mixture in which B predominated. After completion 
of the denaturation process (>70 °C), the signal was sharpened and a linear 
temperature-dependent passive shift downfield (vii in Figure 39a) was again 
observed. As seen in Figure 39b, a unique negative S-curve (19F shift vs 
temperature) was obtained. The sharp inflection point of the curve referred to 
thermal denaturation, consistent with the profile obtained by UV spectroscopy (Tm 



























Figure 39. Thermal melting of the TAR model A. (a) Corresponding 19F NMR spectra at 
different temperatures and (b) profile of the 19F resonance shifts versus temperature of the 
TAR model  ( ) and a reference 5-[4,4,4-trifluoro-3,3-bis(trifluoromethyl)but-1-ynyl]-2 -
deoxyuridine ( ). 
 
 




3.2.2.2 Invasion of short oligomers to TAR model 
Two 2 -O-methyl oligoribonucleotide invaders, viz. 5 -CUC CCA GGC UCA-3  
(ON12) and 5 -CA GGC UCA-3  (ON8), were chosen for invasion studies of the 
TAR model (Scheme 12). The selected 12-mer ON12 has been previously 
demonstrated to inhibit Tat-dependent in vitro transcription in HeLa cell nuclear 
extract.51 Additionally, a pseudo-half-knotted TAR RNA complex has been 
reported to be formed with the two-nucleotide-shifted 12-mer 5 -CCC AGG CUC 
ACA-3 .138 On the other hand, ON8 is of special interest, because a weak interaction 
is expected to occur between ON8 and TAR model A resulting in a dynamic 
equilibrium that is difficult to study by other methods. For the titration experiments 
the 2´-O-methyl invader oligomers ON8 and ON12 were gradually added as 1 and 5 







3.2.2.2.1 Invasion of ON12 
Upon titration of A with ON12 at 25 °C (see A C12 and D12 in Scheme 12), the 
signal of A disappeared, and a novel signal at 66.89 ppm (Figure 40) appeared 
almost quantitatively (Kd = 0.11 ± 0.06 mol L 1 at 25 °C), referring most likely to 
formation of C12 by chain invasion.   
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Figure 40. Titration of the TAR model A with ON12.  
 





[C] = concentration of the complex (C8 or C12) 
[ONtot] = total concentration of the 2’-O-methyl oligoribonucleotide (ON8 or ON12) 
[ON] = concentration of the free ON8 or ON12 
[A] = concentration of the free 19F labelled TAR model A. 
[Atot] = initial concentration of A 




Interestingly, on increasing the temperature, gradual conversion of this signal to 
another one 0.05 ppm upfield took place (i vi in Figure 41), the two signals being 
equal at 45 °C (v in Figure 41). At 51 °C, they were merged to a single broad signal 
(vi in Figure 41). As mentioned above, a pseudo-half-knotted TAR RNA complex 
has previously been characterized.138 Most likely, the first observed signal referred 
to a macro-looped complex that resembles the half-knot C12 (Scheme 12) and the 
latter signal to a stable open-chain invasion complex D12. When the temperature 
was further increased, the signal of D12 was almost linearly shifted downfield, and 
eventually it merged with the signal of the single-stranded form B of the TAR 
model (vii in Figure 39). Thermal denaturation of D12, hence, took place at a higher 
temperature than the conversion of the hairpin TAR (A) to an open-chain form (B), 
consistent with the Tm value of 65.7 °C obtained by thermal UV profile. The signals 
of D12 and B overlap as expected, since the melting of D12 was not accompanied by 
any marked change in the immediate vicinity of the 19F probe. The temperature-
dependent behavior of the C12 D12 complex was additionally characterized by 1H 
NMR spectroscopy of the imino region involved in Watson-Crick base pairing. 1H 
NMR spectroscopy supported qualitatively the 19F NMR spectroscopic data, but 
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Figure 41. Thermal melting of the complex C12. 
 
 




























3.2.2.2.2 Invasion of ON8 
Titration with an 8-mer oligonucleotide, ON8, could also be successfully 
monitored. As expected, the affinity was weak, but a 1:1 complex was formed (Kd 
= 18.5 ± 1.1 mol L 1 at 25 °C, Figure 42). At 25 °C and in an excess (15 equiv) of 
ON8, the 19F signal referring to the macro-looped invasion complex C8 ( 66.90 
ppm, Figure 42) predominated.  
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Figure 42. Titration of the TAR model A with ON8.  
 
As with ON12, the complex exhibited two, albeit broader and partially overlapped, 
signals at a higher temperature (C8/D8). In addition, the signal of the hairpin form 
A of the uncomplexed TAR model was increased upon heating (from 25 to 45 °C, 
viii x in Figure 43a). Owing to this dynamic equilibrium, a clear thermal 
denaturation temperature for the complex could not be determined. However, 
compared to the signal of A the relative peak area of the complex signal suddenly 
started to increase on passing 45 °C (xi xiv in Figure 43a). This phenomenon 
occurred clearly prior to thermal unwinding of A. The relative peak areas of the 19F 
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resonance signals at various temperatures are seen in Figure 43b. It is worth noting 
that the composition of the structures cannot be reliably determined, since signals 
may be sums of overlapped coalescent and scattered signals. In spite of the 
potential integration errors, the profile in Figure 43b illustrates competition of 
intramolecular (A B) and intermolecular (D B) hybridization prior to thermal 
unwinding of A, and the invasion clearly took over on passing 45 °C. In other 
words, at a temperature higher than 45 °C, the predominant complex was D8 and 
the efficiency of ON8 (present in excess) to work as a denaturant increased upon 
heating. At a temperature lower than 45 °C, the predominant invasion complex was 
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Figure 43. (a)  Thermal  melting  of the complex C8,  (b)  relative  peak  areas  of  the  19F 
resonance signals upon heating of the invasion complex C8 (to A and D8) in the presence 
( ) and absence ( ) of neomycin B (see Section 3.2.2.2.3). 
 
 




Thermal 19F profiles (19F shift vs temperature) obtained by heating C8 and C12 
complexes are shown in Figure 44. The UV melting profile of the mixture A + ON8 
(15 equiv) exhibited Tm = 58.9 °C, which was lower than that of the thermal 
denaturation of the TAR model A to an open-chain form B (60.7 °C) without ON8. 
Noteworthy, since the UV-studies were performed in a diluted 2 µmol L-1 solution 
of A, the weak complexes are more dissociated. 
 



























Inf lection point gives Tm
Open chain complex (D) follows upfield curve
Macro-looped complex (C) follows downf ield curve
19F nucleoside reference
The signals of D and B expectedly overlap,
since melting of D is not accompanied by any
marked change in the immediate vicinity of the 19F probe
 
 
Figure 44. Profiles of the 19F NMR resonance shifts versus temperature. Shifts obtained 
by heating C8 ( ), A ( ), C12 ( , ) and 5-[4,4,4-trifluoro-3,3-
bis(trifluoromethyl)but-1-ynyl]-2 -deoxyuridine ( ) as a reference.  
 
3.2.2.2.3 Invasion of ON8 in the presence of neomycin B 
Titration of A with ON8 was additionally performed in the presence of a known 
TAR ligand, neomycin B, which was used 1.0 equiv compared to A. Binding of 
neomycin itself led to formation of two additional broad 19F signals (peaks with 
asterisks, vii in Figure 45), which skewed integration of relative peak areas at low 
ON8 concentrations (viii in Figure 45). Upon further titration, the signal of the 
complex was sharpened (ix xi), and a ballpark estimate of the Kd value (11 ± 7 
mol L 1 at 25 °C) could be determined. As a result, the presence of neomycin B 
ligand somewhat enhanced the invasion (compare to Kd = 18.5 ± 1.1 mol L 1). 










































Figure 45. 19F NMR spectra upon titration of A with ON8 in the absence (a, ii vi) and in 
the presence (b, viii xi) of neomycin. 
 
The site-specific binding of neomycin is known to occur below the bulged 
nucleotides of native TAR region through the minor groove.23,210 Therefore, it was 
expected that any change in the invasion efficiency is related to this specific 
binding and is confined to low temperatures. Upon heating of the mixture of A, 
ON8, and neomycin (1:2:1 n/n/n), the equilibrium inconsistently behaved like the 
mixture without neomycin, and the 19F shift vs temperature followed the profile of 
C8 (Figure 43b, 44).IV Although the temperature-dependent behavior did not show 
mechanistic details, neomycin clearly enhanced the invasion. For example, in these 
experiments, a 1:2 mixture of A and ON8 in the presence of neomycin resulted in 
approximately the same conversion as obtained by the corresponding 1:8 mixture 
without neomycin (xi compared to v in Figure 45). The UV melting profile of the 
mixture gave Tm = 62.5 °C, which was higher than that of the mixture without 







Altogether five different nucleosidic building blocks that allow the development of 
post-synthetic click-conjugation strategies were synthesized in high yield: 4´-C-
azidomethylthymidine 3´-(H-phosphonate) (1), 4´-C-[N,N-di(4-pentyn-1-
yl)aminomethyl]thymidine 3´-phosphoramidite (2), 4´-C-[N-methyl-N-(4-pentyn-1-
yl)aminomethyl]thymidine 3´-phosphoramidite (3), 2´-O-[(2-
azidoethoxy)methyl]cytidine 3´-(H-phosphonate) (4) and 2´-O-[(2-
bromoethoxy)methyl]cytidine 3´-phosphoramidite (5). Click chemistry, referring 
here to the Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddition between azide and 
alkyne, was proven to be highly efficient and orthogonal conjugation method for 
oligonucleotides incorporating monomers 1-4. Ligands included azido or alkynyl 
functionalized derivatives of neutral carbohydrates, aminoglycosides and p-
aminomethylbenzene. Nucleoside 2 bearing two 4-pentyn-1-yl groups enables high 
density functionalization of oligonucleotides whereas nucleosides 1, 3 and 4 allow 
one-armed conjugations. Click reactions were performed mostly on a solid support, 
but they can also be carried out in solution. The parallel use of monomers 1-4 with 
monomer 5 having 2´-O-[(2-bromoethoxy)methyl]-branch enables double click 
conjugation strategy. That is, two different ligands can be attached to the 
oligonucleotide when after first click reaction of monomers 1-4, the same reaction 
is utilized to conjugate the second ligand after conversion of the bromo substituent 
in monomer 5 to azido group on solid support. This was demonstrated with 
oligonucleotides containing building blocks 4 and 5. 
 
In oligonucleotide assembly on an automated DNA/RNA synthesizer, the azido-
bearing monomers 1 and 4 were introduced to the chain applying H-phosphonate 
coupling instead of the conventional phosphoramidite approach, because of the 
intramolecular Staudinger reaction between azido and phosphoramidite groups. 
However, the presence of an azido group in the growing solid-supported 
oligonucleotide chain did not disturb the phosphoramidite coupling of subsequent 
monomers and thus, the Staudinger reaction seems to interfere with only genuinely 
intramolecular reactions. This observation is of practical value, since 
phosphoramidite method is applied in majority of synthesizers and with 
commercially available building blocks. Therefore, H-phosphonate coupling was 
used only for monomers 1 and 4 and otherwise phosphoramidite method was 
applied for oligonucleotide synthesis. 
 
Importantly, monomers 1-4 were shown to allow intrachain conjugations of the 
oligonucleotides as they were well accommodated to the duplexes formed with 
complementary DNA and 2´-O-Me RNA targets. The melting temperature studies 
demonstrated the utility of 2´- and 4´-modified nucleosides 1-4 in 
glycoconjugations. The 4´-modified oligonucleotides containing one to four 
mannose ligands in the central part of the chain formed equally stable duplexes 
with complementary 2´-OMe RNA as the corresponding unmodified DNA 
sequence. At high salt content, the mannose-conjugation was even stabilizing. 





hybridization properties and all amino group bearing conjugates stabilized the 
DNA DNA duplex significantly and the DNA 2´-O-methyl RNA duplex notably.  
 
In the second part of the Results and Discussion, the applicability of 19F NMR 
spectroscopy for the characterization of RNA invasion was demonstrated. 5-[4,4,4-
Trifluoro-3,3-bis(trifluoromethyl)but-1-ynyl]-2 -deoxyuridine fluorine probe was 
incorporated into the HIV-1 TAR RNA model, which was then targeted with two 
-O-methyl oligoribonucleotide invaders, viz. 5 -CUC CCA GGC UCA-3  (ON12) 
and 5 -CA GGC UCA-3  (ON8). The Kd values for RNA-ligand interaction were 
determined with titration studies and the methodology allowed the detection of 
temperature-dependent behavior of the complexes. Additionally, the invasion of 
ON8 to the TAR model was shown to be enhanced in the presence of a known TAR 
ligand neomycin B. 19F NMR provided a novel approach for detailed monitoring of 







The synthetic methods discussed in the thesis are reported in the original 
publications except for the synthesis of 3´-O-(4,4´-dimethoxytrityl)-4´-C-
hydroxymethylthymidine (11), which has been previously reported168 but with 
undetailed description and with different transient protecting group in 5´-OH (See  
below). Also the formation of compounds 23 and 26 bearing an oxetane-ring 
structure are descripted here. The oligonucleotides were synthesized on an Applied 
Biosystems 392 DNA synthesizer and the protocol details for oligonucleotide 
assembly as also for click-conjugations are described in the Results and Discussion 
and in original publications.  
 
For the characterization of compounds obtained by solution synthesis 1H NMR, 13C 
NMR, 31P NMR and HRMS methods have been employed when applicable. RP 
HPLC analysis of oligonucleotide conjugates were performed using either Supelco 
Ascentis C18 (150 × 4.6 mm, 5 µm) analytical column (for ONs 58, 59, 66-70) or 
Thermo ODS Hypersil C18 (250 × 4.6 mm, 5 µm) column (for ONs 60-65, 71-82). 
UV detection at 260 nm was used. Detailed chromatographic conditions are given 
in the Results and Discussion. Electropherograms were obtained by capillary zone 
electrophoresis using a fused silica capillary (75 m, 50 cm), inverted polarity, 
citrate buffer (0.2 mol L-1, pH 3.1), -30 kV voltage and detection wavelength of 
254 nm.  
 
 
Synthesis of 3´-O-(4,4´-dimethoxytrityl)-4´-C-hydroxymethylthymidine: 
 
3´-O-(4,4´-Dimethoxytrityl)thymidine (10). To a solution of thymidine 9 (5.16 g, 
21.3 mmol) in 80 mL of dry pyridine, benzoyl chloride (2.5 mL, 21.5 mmol) was 
added on an ice bath. The mixture was stirred overnight at room temperature and 
evaporated. The residue was dissolved in dichloromethane and extracted with 
water. The organic fraction was dried with Na2SO4, evaporated and subjected to the 
next step without further purification. The crude 5´-O-benzoylthymidine was 
dissolved in dry pyridine (60 mL) and 4,4´-dimethoxytrityl chloride (6.65 g, 19.6 
mmol) was added. The reaction was heated at 50 ºC overnight and after 
evaporation, the residue was partitioned between dichloromethane and water. The 
organic fraction was dried with Na2SO4 and evaporated. The crude 5´-O-benzoyl-
3´-O-(4,4´-dimethoxytrityl)thymidine was dissolved in MeOH (120 mL) and to 
remove the benzoyl protection, sodium methoxide [sodium (1.00 g, 43.0 mmol) in 
MeOH (50 mL)] was added. After stirring the reaction at room temperature for 2 h, 
the mixture was evaporated and purified by silica gel chromatography (60-100 % 
ethyl acetate in petroleum ether + 0.1 % triethylamine). This afforded compound 10 
(8.36 g, 78%) as a white solid foam. The given yield is calculated from the 
restrictive compound DMTrCl, but since the first benzoylation step goes 
quantitatively (isolation data not shown here) the given yield can be considered as 
an overall yield of the three steps. 1H NMR (500 MHz, CDCl3) ppm  8.56 (br s, 1H), 





(dd, 1H, J = 8.8 Hz, 5.8 Hz), 4.36 (m, 1H), 3.97 (m, 1H), 3.79 (s, 6H), 3.66 (m, 
1H), 3.32 (m, 1H), 2.46 (m, 1H), 1.93 (m, 1H), 1.85 (s, 3H), 1.70 (m, 1H); 13C 
NMR (125 MHz, CDCl3) ppm  163.5, 158.8, 150.3, 145.1, 137.2, 136.3, 136.2, 
130.3, 130.2, 128.3, 128.0, 127.1, 113.4, 113.3, 111.0, 87.5, 87.2, 86.6, 74.3, 62.6, 
55.3, 38.7, 12.5. 
 
3´-O-(4,4´-Dimethoxytrityl)-4´-C-hydroxymethylthymidine (11). To the 
suspension of compound 10 (3.35g, 6.2 mmol) and DCC (3.79g, 18.4 mmol) in 
DMSO (23 mL), a solution of trifluoroacetic acid (0.24 mL, 3.1 mmol) and 
pyridine (0.73 mL, 9.1 mmol) in DMSO (20 mL) was added on an ice bath and the 
reaction proceeded at room temperature overnight. Ethyl acetate was added to the 
reaction mixture and prior to the extraction with water and brine, the precipitated 
DCU (N,N'-dicyclohexylurea) was removed by filtration. The organic phase was 
separated, dried with Na2SO4 and evaporated to dryness. The received aldehyde 
product was then subjected to the aldol condensation followed by Cannizzaro 
reduction. The crude product was dissolved in 1,4-dioxane (170 mL) and 
formaldehyde (47 mL of 37% solution) and aq NaOH (93 mL of 2.0 mol L-1 
solution) was added. After stirring overnight at room temperature and evaporation, 
the reaction mixture was extracted with dichloromethane and water. The organic 
fraction was dried with Na2SO4, evaporated and purified by silica gel 
chromatography (3-10% MeOH in dichloromethane + 0.1 % triethylamine). The 
product (11, 3.37 g) was isolated in 95% yield. 1H NMR (500 MHz, CDCl3) ppm  
9.40 (br, 1H), 7.45-7.42 (m, 2H), 7.37-7.27 (m, 6H), 7.23 (m, 1H), 6.86-6.79 (m, 
5H), 6.30 (dd, 1H, J = 8.3 Hz, 4.3 Hz), 4.54 (dd, 1H, J = 8.0 Hz, 8.0 Hz), 4.09 (d, 
1H, J = 12.5 Hz), 3.97 (d, 1H, J = 11.5 Hz), 3.82-3.74 (m, 7H), 3.43 (d, 1H, J = 
11.0 Hz), 1.98 (m, 1H), 1.71 (s, 3H), 1.16 (m, 1H);  13C NMR (125 MHz, CDCl3) 
ppm  163.7, 158.9, 158.9, 150.7, 145.1, 136.6, 136.1, 135.9, 130.4, 128.3, 128.0, 
127.3, 113.3, 113.3, 111.2, 89.2, 87.2, 82.8, 72.5,  62.7, 61.7, 55.3, 38.7, 12.3. 
 
 
The formation of oxetane compounds 23 and 26: 
 
5´-O-(4,4´-Dimethoxytrityl)-O3´,4´-methylenethymidine (23). 5´-O-(4,4´-
Dimethoxytrityl)-4´-C-tosyloxymethylthymidine (22, 0.80 g, 1.1 mmol) was 
dissolved in DMF (7 mL) and pyridine (1.8 mL) and sodium azide (0.36 g, 5.5 
mmol) was added. The reaction mixture was heated at 140 °C for 8 h and 
evaporated. The residue was partitioned between dichloromethane and water. The 
organic fraction was dried with Na2SO4, evaporated and purified by silica gel 
chromatography (50-100% ethyl acetate in petroleum ether). The compound 23 
(0.35g) was isolated as white foam in 57% yield. The desired product 4´-C-
azidomethyl-5´-O-(4,4´-dimethoxytrityl)thymidine (15) was not detected.  1H NMR 
(500 MHz, CDCl3) ppm  8.57 (br, 1H), 7.48 (d, 1H, J = 1.0 Hz), 7.40-7.37 (m, 2H), 
7.32-7.24 (m, 7H), 6.89 (dd, 1H, J = 8.8 Hz, 5.8 Hz), 6.86-6.82 (m, 4H), 5.37 (d, 
1H, J = 4.5 Hz), 4.54 (d, 1H, J = 7.5 Hz), 4.42 (d, 1H, J = 8.0 Hz), 3.80 (s, 3H), 
3.80 (s, 3H), 3.55-3.50 (m, 2H), 2.69 (dd, 1H, J = 14.0 Hz, 5.8 Hz), 1.90 (m, 1H), 





144.3, 135.3, 135.2, 130.0, 128.1, 128.0, 127.2, 113.3, 112.0, 87.5, 86.7, 86.6, 85.4, 
78.3, 63.2, 55.3, 39.4, 11.8; HRMS (FAB-): [M-H] calcd 555.2131, obsd 555.2149. 
 
3´-O-(4,4´-Dimethoxytrityl)-O5´,4´-methylenethymidine (26). -O-(4,4 -
Dimethoxytrityl)-4 -C-propargyloxymethyl-O2,5 -anhydrothymidine (24, 0.57 g, 
1.0 mmol) and 3 -O-(4,4 -dimethoxytrityl)-4 -C-pentynyloxymethyl-O2,5 -
anhydrothymidine (25, 0.64 g, 1.0 mmol) were dissolved in 1,4-dioxane (15 mL) 
and aqueous NaOH (4.5 mL, 2 mol L-1, 9.0 mmol) was added. The mixtures were 
stirred overnight at room temperature and partitioned between ethyl acetate (150 
mL) and water (20 mL). The organic phases were separated, dried with Na2SO4, 
and evaporated to dryness. In both cases, the compound 26 was isolated in >90% 
yield and, hence, the desired products 3´-O-(4,4´-dimethoxytrityl)-4´-C-
propargyloxymethylthymidine and 3´-O-(4,4´-dimethoxytrityl)-4´-C-
pentynyloxymethylthymidine were not detected . 1H NMR (500 MHz, CDCl3) ppm  
8.50 (br, 1H), 7.58-7.54 (m, 2H), 7.50-7.41 (m, 4H), 7.36-7.31 (m, 2H), 7.27 (m, 
1H), 6.91-6.85 (m, 4H), 6.69 (s, 1H), 5.78 (dd, 1H, J = 7.3 Hz, 4.8 Hz), 5.43 (d, 
1H, J = 6.5 Hz), 4.82 (d, 1H, J = 7.0 Hz), 4.78 (d, 1H, J = 7.5 Hz), 4.60 (d, 1H, J = 
7.0 Hz), 4.39 (dd, 1H, J = 7.0 Hz, 6.5 Hz), 3.82 (s, 6H), 1.88 (s, 3H), 1.64 (m, 1H), 
1.28 (m, 1H); 13C NMR (125 MHz, CDCl3) ppm 163.6, 158.9, 149.8, 145.1, 136.2, 
136.1, 135.9, 130.4, 130.3, 128.3, 128.1, 127.3, 113.4, 113.4, 111.0, 87.3, 86.2, 
86.0, 80.9, 79.1, 75.2, 55.3, 38.0, 12.5; ESI-MS: [M+Na] calcd 579.2, obsd 579.4. 
 
5.2 Melting temperature studies 
The melting curves (absorbance versus temperature) were measured at 260 nm on a 
Perkin-Elmer Lambda 35 UV-vis spectrometer equipped with a Peltier 
temperature-controller except for ONs 58, 59, 66-70, which were measured using 
an older instrument Perkin-Elmer Lambda 2 UV-vis spectrometer. The results 
obtained by these instruments differ from each other because the temperature is 
measured differently. While the newer machine detects the temperature from 
reference cuvette directly, the old one can measure only the temperature of the 
peltier element that rounds the cuvette. As a consequence, the obtained Tm values 
are not directly comparable with each other. The temperature was changed at a rate 
of 0.5 ºC / min (from 20 to 90 ºC). The measurements were performed in 10 mmol 
L-1 potassium phosphate buffer (pH 7) containing 0.1 mol L-1 or 1.0 mol L-1 NaCl 
except in the studies with HIV-1 TAR RNA, in which case 25 mM NaH2PO4 buffer 
(pH 6.5) was used. The oligonucleotides and their targets were used at a 
concentration of 2 µmol L-1. Only in measurements of HIV-1 TAR RNA with 
invader ON8, the invader was used in larger quantities (See supporting information 
of the original publication IV). Tm values were determined as the maximum of the 
first derivate of the melting curve. 
 
5.3 Invasion studies of HIV-1 TAR RNA using NMR 
Oligonucleotides (triethylammonium salts) used in the 19F NMR studies were 
lyophilized to dryness and dissolved in 25 mmol L-1 NaH2PO4-buffer (pH 6.5) in 





and 5 mmol L-1 solutions to a 20 mol L-1 solution of 19F labelled TAR model A. 
For studies with 1H NMR, the fluorine-labeled TAR model A and unmodified 
native TAR sequence A´ (both 100 mol L-1) were measured in 25 mmol L-1 
NaH2PO4-buffered (pH 6.5) D2O-H2O (1:9, v/v) and 1.0 equiv of ON12 (100 mol 
L-1) was added to NMR tubes. Prior to each spectroscopic detection, the mixtures 
were heated to 90°C for 1 minute and then allowed to cool down to room 
temperature. 
 
19F NMR spectra were recorded at a frequency of 376.1 MHz on a Bruker Avance 
400 MHz spectrometer. Typical experimental parameters were chosen as follows: 
19F excitation pulse 12.6 s, acquisition time 0.675 s, relaxation delay 1.0 s and 
usual number of scans were 2400 or 4800. 19F resonances were referenced relative 
to external CCl3F. 1H NMR spectra were recorded at a frequency of 500.1 MHz on 
a Bruker Avance 500 MHz spectrometer. Water was suppressed by excitation 
sculpting technique.211 Sample temperature was calibrated by using known shifts of 
ethylene glycol in different temperatures.  
 
Kd values were calculated from relative peak areas of 19F resonance signals of the 
free TAR model A and of the complexes (C8 and C12), according to following 
equations: 
 
Kd[C] = [A][ON] 
 
[A] + [C] = [Atot] 
 
[ON] = [ONtot] – [C] 
 





[C] = concentration of the complex (C8 or C12) 
[ONtot] = total concentration of the 2’-O-methyl oligoribonucleotide (ON8 or ON12) 
[ON] = concentration of the free ON8 or ON12 
[A] = concentration of the free 19F labelled TAR model A. 
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